

Soudeh Ghafouri-Fard

Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Velenjak St, Chamran Highway Tehran, Iran

Email: s.ghafourifard@sbmu.ac.ir

ORCID: 0000-0002-0223-499X

Scopus Author ID: 55387443600

PERSONAL INFORMATION

Date of Birth: June 29, 1978

Gender: Female

Place of Birth: Tehran, Iran

Cell Phone: (+98) 9123308784

Marital Status: Married

Phone: (+98) 2123872572

EDUCATION

Ph.D. Doctor of Philosophy (Ph.D.) in Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran (2004-2009)
Thesis: Expression Analysis of 5 Testis Specific Genes (ODF, PASD1, SPATA19, NYD-SP8, LEMD1) in GI Adenocarcinomas, Prostate Cancer and Basal Cell Carcinoma and Analysis of Antibody Production against them

GP Doctor of Medicine (M.D.), Tehran University of Medical Sciences, Tehran, Iran (1997-2004)
Thesis title: Evaluation of Epidemiologic Risk Factors for Squamous Cell Carcinoma of Esophagus in Iranian Patients Referred to Imam Khomeini Hospital

HONORS

- Winner of Razi award, 2022
- Researcher award of assistant professor, 15th Aboreyhan Birooni festival, Iran, 2014.
- Researcher award of associated professor, 19th Aboreyhan Birooni festival, Iran, 2018.
- Winner of “Gold Award” and won First Place in the “Youth Science Festival” (Iran)
- Ranked seventh in the entrance examination in 1997 in science groups among 352645 participants
- Winner of “National Festival for Selection of 110 Example Youth” (Iran)
- Ranked first among PhD students of Medical Genetic Department of Tehran University of Medical Sciences achieving grade average of 18.8 out of 20

CITATION INDICES

Scopus

Citations: 8299 total citations by 6088

h-index: 42

i10-index: 146

Google Scholar

Total Citations: 10400

h-index: 47

i10-index: 327

SELECTED PUBLICATIONS

JOURNAL ARTICLES

1. **Ghafouri-Fard S**, Harsij A, Pourmoshtagh H, Taheri M. A review on the role of FOXD2-AS1 in human disorders. Pathology Research and Practice. 2024 [accepted].

2. ..., **Ghafouri-Fard S**,... Meta-analysis of microarray data to determine gene indicators involved in cisplatin resistance in non-small cell lung cancer. *Cancer Reports*. 2023 [accepted].
3. Fathi M, Ghahghaei-Nezamabadi A, **Ghafouri-Fard S**. Emerging role of lncRNAs in the etiology of recurrent implantation failure. *Pathology Research and Practice*. 2023 [accepted].
4. Janamiri S, Hussen BM, Heidari S, Taheri M, Eslami S, Dadmehr M, **Ghafouri-Fard S**, Farahmand S. Abnormal level of VDR-associated lncRNAs in patients with multiple sclerosis. *Biomarkers in Neuropsychiatry*. 2023 [accepted].
5. ..., **Ghafouri-Fard S**,... Hyperglycemic Memory : Observational Evidence to Experimental Inference, *Current Diabetes Reviews*. 2023 [accepted].
6. ..., **Ghafouri-Fard S**. A bioinformatics-based approach and expression assay for identification of dysregulated genes in pituitary adenoma. *Pathology - Research and Practice*. 2023 [accepted].
7. Harsij A, Gharebaghi A, Ghiasian M, Eslami S, **Ghafouri-Fard S**, Taheri M, Sayad A. Expression Analysis of Treg-related lncRNAs in Neuromyelitis Optica Spectrum Disorder. *Multiple Sclerosis and Related Disorders*. 2023 [accepted].
8. **Ghafouri-Fard S**, Askari A, Shoorei H, Seify M, Koohestanidehaghi Y, Hussen BM, Taheri M, Samsami M. Antioxidant Therapy Against TGF- β /SMAD Pathway Involved in Organ Fibrosis. *Journal of Cellular and Molecular Medicine*. 2023 [accepted].
9. Sayad A, Hussen BM, Eslami S, **Ghafouri-Fard S**, Taheri M. Association between HOTAIR genetic variants and risk of obsessive-compulsive disorder. *Biomarkers in Neuropsychiatry*. 2023 [accepted].
10. Hashemi S, **Ghafouri-Fard S**,... A novel homozygote nonsense variant of MSH4 leads to primary ovarian insufficiency and non-obstructive azoospermia. *Molecular Biology Reports*. 2023 [accepted].
11. Khalilian S, Mohajer Z, **Ghafouri-Fard S**. Factor VIII as a novel biomarker for diagnosis, prognosis, and therapy prediction in human cancer and other disorders. *Avicenna Journal of Medical Biotechnology (AJMB)*. 2023 [accepted].
12. **Ghafouri-Fard S**,..., Taheri M. Circular RNAs and Inflammation: Epigenetic Regulators with Diagnostic Role. *Pathology - Research and Practice*. 2023 [accepted].
13. ..., **Ghafouri-Fard S**, ..., Eslami S. Oleoylethanolamide protects mesenchymal stem/stromal cells (MSCs) from oxidative stress and reduces adipogenic related genes expression in adipose-derived MSCs undergoing adipocyte differentiation. *Molecular Biology Reports*. 2023 [accepted].
14. **Ghafouri-Fard S**,..., Taheri M. Associations between GRM7 polymorphisms and obesity in patients selected for sleeve gastrectomy. *Metabolic Brain Disease*. 2023 [accepted].
15. Ahmadi M, ..., **Ghafouri-Fard S**. The hsa-miR-3613-5p, a potential oncogene correlated with diagnostic and prognostic merits in kidney renal clear cell carcinoma. *Pathology - Research and Practice*. 2023 [accepted].

16. Ahmadi M, ..., **Ghafouri-Fard S**. Circular RNA_0000285: A novel double-edged sword circular RNA in human malignancies. *Pathology - Research and Practice*. 2023 [accepted].
17. Taheri M, Sadeghi A, Gharebaghi A, Ghiasian M, Eslami S, Khalilian S, Sayad A, **Ghafouri-Fard S**. Significant up-regulation of lncRNAs in neuromyelitis Optica spectrum disorder. *Scientific Reports*. 2023 [accepted].
18. Taheri M, Pourtavakoli A, Eslami S, **Ghafouri-Fard S**, Sayad A. Assessment of expression of Calcium signaling related lncRNAs in epilepsy. *Scientific Reports*. 2023 [accepted].
19. **Ghafouri-Fard S**, Safarzadeh A, Hassani Fard Katiraei S, Hussen BM, Hajiesmaeili M. Diverse functions of miR-328 in the carcinogenesis. *Pathology - Research and Practice*. 2023 [accepted].
20. **Ghafouri-Fard S**, ..., Taheri M. LncRNA SNHG12: A Budding Star in Human Diseases. *Pathology - Research and Practice*. 2023 [accepted].
21. Khalilian S, ..., **Ghafouri-Fard S**. Emerging functions and significance of circCDYL in human disorders. *Molecular Biology Reports*. 2023 [accepted].
22. **Ghafouri-Fard S**, ... Expression of cAMP and oxidative phosphorylation related lncRNAs in non-functioning pituitary adenomas. *Journal of Cellular and Molecular Medicine*. 2023 [accepted].
23. **Ghafouri-Fard S**, Nicknam A, Safarzadeh A, Eslami S, Samsami M, Jamali E. Expression analysis of PPAR-related lncRNAs in breast cancer. *Pathology - Research and Practice*. 2023 [accepted].
24. **Ghafouri-Fard S**, ... Construction of ceRNA Network and Identification of Hub Differentially Expressed Genes Associated with Breast Cancer using Reanalysis of Microarray Dataset: A Systems Biology Approach. *Pathology - Research and Practice*. 2023 [accepted].
25. **Ghafouri-Fard S**, Askari A, Zangoosie A, Shoorei H, Pourmoshtagh H, Taheri M. Non-Coding RNA Profile for Natural Killer Cell Activity. *Molecular and Cellular Probes*. 2023 [accepted].
26. Toghi M, Bitarafan S, **Ghafouri-Fard S**. Pathogenic Th17 cells in autoimmunity with regard to rheumatoid arthritis. *Pathology - Research and Practice*. 2023 [accepted].
27. **Ghafouri-Fard S**, ... Identification of diagnostic biomarkers via Weighted Correlation Network Analysis in colorectal cancer using a system biology approach. *Scientific Reports*. 2023 [accepted].
28. Abolghasemi S, ..., **Ghafouri-Fard S**. Gene expression analysis of SOCS, STAT and PIAS genes in lung cancer patients. *Pathology - Research and Practice*. 2023 [accepted].
29. Khalilian S, ..., **Ghafouri-Fard S**. circWHSC1: A circular RNA piece in the human cancer puzzle. *Pathology - Research and Practice*. 2023 [accepted].
30. Hashemi S, ..., **Ghafouri-Fard S**. Acute Kidney Injury (AKI) in COVID-19: In silico Identification of LncRNA-MiRNA-Gene Networks and Key Transcription Factors. *Current Pharmaceutical Design*. 2023 [accepted].

31. Hashemi S,..., **Ghafouri-Fard S**. Meta-analysis of microarray data to determine gene indicators involved in the cisplatin resistance in ovarian cancer. *Cancer Reports*. 2023 [accepted].
32. **Ghafouri-Fard S**,... A concise review on the role of MIR100HG in human disorders. *Journal of Cellular and Molecular Medicine*. 2023 [accepted].
33. Hussen BM, Rasul MF, Abdullah SR, Hidayat HJ, Hama Faraj GS, Abodi Ali F, A Salihi, Baniahmad A, **Ghafouri-Fard S**, Rahman M, Glassy MC, Branicki W, Taheri M. Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges. *Military Medical Research*. 2023 [accepted].
34. Mokhtari M, Gholipour M, Eslami S, Abak A, Hussen BM, Rakhshan A, **Ghafouri-Fard S**. Expression analysis of cytoskeleton regulator RNA and Cyclin Dependent Kinase Inhibitor 2B genes in breast cancer. *Human Antibodies*. 2023 [accepted].
35. **Ghafouri-Fard S**,... Nanoparticle-mediated delivery of microRNAs-based therapies for treatment of disorders . *Pathology - Research and Practice*. 2023 [accepted].
36. **Ghafouri-Fard S**,... Expression pattern of lncRNAs in pituitary adenomas. *Pathology - Research and Practice*. 2023 [accepted].
37. **Ghafouri-Fard S**,... The interaction between miRNAs and hazardous materials. *Non coding RNA research*. 2023 [accepted].
38. **Ghafouri-Fard S**,...Interaction between SIRT1 and non-coding RNAs in different disorders. *Frontiers in Genetics, section RNA*. 2023 [accepted].
39. **Ghafouri-Fard S**,... A review on the role of CASC11 in cancers. *Frontiers in Cell and Developmental Biology, section Cancer Cell Biology*. 2023 [accepted].
40. **Ghafouri-Fard S**,... Expression of LINC00174 in different cancers: review of the literature and bioinformatics analyses. *Pathology - Research and Practice*. 2023 [accepted].
41. **Ghafouri-Fard S**,... Single cell RNA-seq analysis with a systems biology approach to recognize important differentially expressed genes in pancreatic ductal adenocarcinoma compared to adjacent non-cancerous samples by targeting pancreatic endothelial cells. *Pathology - Research and Practice*. 2023 [accepted].
42. **Ghafouri-Fard S**,... Association between rs217727 and rs2839698 H19 polymorphisms and obesity. *Biochemical Genetics*. 2023 [accepted].
43. ..., **Ghafouri-Fard S**. Carcinogenic Roles of MAFG-AS1 in Human Cancers. *Clinical and Translational Oncology*. 2023 [accepted].
44. Khalilian S,..., **Ghafouri-Fard S**. circGFRA1: A circular RNA with important roles in human carcinogenesis. *Pathology - Research and Practice*. 2023 [accepted].
45. Khalilian S,..., **Ghafouri-Fard S**. The important role of miR-770 as a novel potential diagnostic and therapeutic target for human cancer and other diseases. *Pathology - Research and Practice*. 2023 [accepted].

46. **Ghafouri-Fard S**,... A review on the role of genetic mutations in the autism spectrum disorder. *Molecular Neurobiology*. 2023 [accepted].
47. **Ghafouri-Fard S**,... A review on the role of MYC-Induced Long Non-Coding RNA in human disorders. *Pathology - Research and Practice*. 2023 [accepted].
48. **Ghafouri-Fard S**,... Dysregulation of PVT1 and NEAT1 lncRNAs in pituitary adenomas. *Pathology - Research and Practice*. 2023 [accepted].
49. ..., **Ghafouri-Fard S**. MYC and Non-Small Cell Lung Cancer: A comprehensive review. *Human Gene*. 2023 [accepted].
50. Hantoushzadeh S, Younesi S, Taheri Amin MM, Saadati P, Jamali S, Nassiri S, Modarresi MH, Savad S, Delshad S, Soleiman Meiguni Z, Amidi S, Navidpour F, Yazdani B, Karimi Farani A, Saleh M, **Ghafouri-Fard S**. Impact of COVID-19 and vaccination on first and second trimester screening results. *Cytokine*. 2023 [accepted].
51. **Ghafouri-Fard S**,... A review on the role of GHET1 in different cancers. *Pathology - Research and Practice*. 2023 [accepted].
52. ..., **Ghafouri-Fard S**. Roles of non-coding RNAs in Cell Death Pathways Involved in the Treatment of Resistance and Recurrence of Cancer. *Pathology - Research and Practice*. 2023 [accepted].
53. **Ghafouri-Fard S**,... A review on the role of LINC00472 in malignant and non-malignant disorders. *Pathology - Research and Practice*. 2023 [accepted].
54. **Ghafouri-Fard S**,... A review on the role of HAND2-AS1 in cancer. *Clinical and Experimental Medicine*. 2023 [accepted].
55. Taheri M, Askari A, Hussen BM, **Ghafouri-Fard S**, Kiani A. Role of MAGI2-AS3 in malignant and non-malignant disorders. *Pathology - Research and Practice*. 2023 [accepted].
56. **Ghafouri-Fard S**, Hussen BM, Rasool Abdullah S, Taheri M, Jamali E, Shojaei S. Dysregulation of non-coding RNAs in Wilms tumor. *Pathology - Research and Practice*. 2023 [accepted].
57. **Ghafouri-Fard S**, Shoorei H, Dong P, Poornajaf Y, Hussen BM, Taheri M, Akbari Dilmaghani N. Emerging functions and clinical applications of exosomal microRNAs in diseases. *Non-coding RNA Research*. 2023 [accepted].
58. **Ghafouri-Fard S**,... Up-regulation of MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 lncRNAs in non-functioning pituitary adenoma. *Journal of Cellular and Molecular Medicine*. 2023 [accepted].
59. **Ghafouri-Fard S**,... A review on the role of ZEB1-AS1 in human disorders. *Pathology - Research and Practice*. 2023 [accepted].
60. **Ghafouri-Fard S**,... Sarcopenia and non-coding RNAs: a comprehensive review. *Journal of Cellular Physiology*. 2023 [accepted].

61. ..., **Ghafouri-Fard S**. In silico identification of potential miRNAs -mRNA inflammatory networks implicated in the pathogenesis of COVID-19. *Human Gene*. 2023 [accepted].
62. **Ghafouri-Fard S**, Safarzadeh A, Hussen BM, Taheri M, Ayatollahi SA. A review on the role of LINC00511 in cancer. *Frontiers in Genetics, section RNA*. 2023 [accepted].
63. **Ghafouri-Fard S**,... Expression analysis of cell cycle related lncRNAs in breast cancer tissues. *Pathology - Research and Practice*. 2023 [accepted].
64. **Ghafouri-Fard S**,... A review on the role of SNHG8 in human disorders. *Pathology - Research and Practice*. 2023 [accepted].
65. **Ghafouri-Fard S**,... A review on the role of NCK1 Antisense RNA 1 (NCK1-AS1) in diverse disorders. *Pathology - Research and Practice*. 2023 [accepted].
66. ...**Ghafouri-Fard S**...Expression analysis of Rho GTPase-related lncRNAs in breast cancer. *Pathology - Research and Practice*. 2023 [accepted].
67. **Ghafouri-Fard S**,...The impact of non-coding RNAs in the pathobiology of eye disorders. *International Journal of Biological Macromolecules*. 2023 [accepted].
68. **Ghafouri-Fard S**, Gholipour M, Eslami S, Hussen BM, Taheri M, Samadian M, Omrani MD. Abnormal expression of MAPK14-related lncRNAs in the peripheral blood of patients with multiple sclerosis. *Non-coding RNA Research*. 2023 [accepted].
69. Taheri M, Badrlou E, Hussen BM, Kashi AH, **Ghafouri-Fard S**, Baniahmad A. Importance of long non-coding RNAs in the pathogenesis, diagnosis and treatment of prostate cancer. *Frontiers in Oncology, section Genitourinary Oncology*. 2023 [accepted].
70. **Ghafouri-Fard S**,... A review on the importance of LINC-ROR in human disorders. *Pathology - Research and Practice*. 2023 [accepted].
71. **Ghafouri-Fard S**,... The significance of N6-methyladenosine-modified non-coding RNAs in different disorders. *European Journal of Pharmacology*. 2023 [accepted].
72. ..., **Ghafouri-Fard S**. Contribution of CRNDE lncRNA in the development of cancer and the underlying mechanisms. *Pathology - Research and Practice*. 2023 [accepted].
73. Savad S, ..., **Ghafouri-Fard S**. A comprehensive overview of SMN and NAIP copy numbers in Iranian SMA patients. *Scientific Reports*. 2023 [accepted].
74. ..., **Ghafouri-Fard S**. ANRIL polymorphisms and risk of obsessive-compulsive disorder. *Heliyon*. 2023 [accepted].
75. Hussen BM, Mohamadtahr S, Abdullah SR, Hidayat H, Rasul MF, Hama Faraj GS, **Ghafouri-Fard S**, Taheri M, Khayamzadeh M, Jamali E. Exosomal Circular RNAs: New player in Breast Cancer Progression and Therapeutic Targets. *Frontiers in Genetics, section RNA*. 2023 [accepted].

76. Mahmoudi-Lamouki R, Kadkhoda S, Hussen BM, **Ghafouri-Fard S**. Emerging role of miRNAs in the regulation of ferroptosis. *Frontiers in Molecular Biosciences, section RNA Networks and Biology*. 2023 [accepted].
77. **Ghafouri-Fard S**, Harsij A, Hussen BM, Abdullah SR, Baniahmad A, Taheri M, Sharifi G. A review on the role of long non-coding RNA prostate androgen-regulated transcript 1 (PART1) in the etiology of different disorders. *Frontiers in Cell and Developmental Biology, section Cancer Cell Biology*. 2023 [accepted].
78. **Ghafouri-Fard S**,... A review on the role of LINC00173 in human cancers. *Pathology Research and Practice*. 2023 [accepted].
79. **Ghafouri-Fard S**, Askari A, Hussen BM, Taheri M, Akbari Dilmaghani N. Role of miR-424 in the carcinogenesis. *Clinical and Translational Oncology*. 2023 [accepted].
80. **Ghafouri-Fard S**, ... A review on the role of ADAMTS9-AS2 in different disorders. *Pathology Research and Practice*. 2023 [accepted].
81. Younesi S, ..., **Ghafouri-Fard S**. Extreme β HCG levels in first trimester screening are risk factors for adverse maternal and fetal outcomes. *Scientific Reports*. 2023 [accepted].
82. **Ghafouri-Fard S**,... Interactions between non-coding RNAs and HIF-1 α in the context of cancer. *European Journal of Pharmacology*. 2023 [accepted].
83. Asadi MR, Abed S, Kouchakali G, Fattahi F, Sabaie H, Moslehian MS, Sharifi Bonab M, Hussen BM, Taheri M, **Ghafouri-Fard S**, Rezazadeh M. Competing Endogenous RNA (ceRNA) Networks in Parkinson's Disease: A Systematic Review. *Frontiers in Cellular Neuroscience, section Cellular Neuropathology*. 2023 [accepted].
84. Sharifi G, Eghtedarian R, Taheri M, Hussen Bm, Eslami S, **Ghafouri-Fard S**, Sayad A. Assessment of Treg related lncRNAs in epilepsy. *Frontiers in Molecular Neuroscience, section Brain Disease Mechanisms*. 2022 [accepted].
85. Dorostgoo Z, Fattahi AS, Moosavi SS, **Ghafouri-Fard S**, Kholghi Oskooei V. Down-regulation of SLC16A-AS1 and LINC00900 lncRNAs in Iranian patients with breast cancer. *Bresat disease*. 2022 [accepted].
86. Khalilian S,..., **Ghafouri-Fard S**. Emerging roles and mechanisms of miR-206 in human disorders: a comprehensive review. *Cancer Cell International*. 2022 [accepted].
87. **Ghafouri-Fard S**, Askari A, Hussen BM, Taheri M, Kiani A. A review on the role of LINC00152 in different disorders. *Pathology - Research and Practice*. 2022 [accepted].
88. Moallemi-Rad L, Ghorbani A, Dadyar M, Hussen BM, Eslami S, Taheri M, Jamali E, **Ghafouri-Fard S**. Expression of Treg-associated lncRNAs in breast cancer. *Pathology - Research and Practice*. 2022 [accepted].

89. Ahmadi Teshnizi S, Shahani P, Taheri M, Hussen BM, Eslami S, Sadeghzadeh Z, **Ghafouri-Fard S**, Sayad A. Expression analysis of NF- κ B-related long non-coding RNAs in bipolar disorder. *Scientific Reports*. 2022 [accepted].
90. **Ghafouri-Fard S**, Askari A, Hussen BM, Taheri M, Kiani A. A review on the role of miR-671 in human disorders. *Frontiers in Molecular Biosciences*, section RNA Networks and Biology. 2022 [accepted].
91. Khalilian S, ..., **Ghafouri-Fard S**. A review on the role of miR-210 in human disorders. *Pathology - Research and Practice*. 2022 [accepted].
92. Taheri M, Safarzadeh A, Hussen BM, **Ghafouri-Fard S**, Baniahmad A. LncRNA/miRNA/mRNA network introduces novel biomarkers in prostate cancer. *Cells* 2022 [accepted].
93. Khalilian S, Abedinlou H, Hussen BM, Hosseini Imani SZ, **Ghafouri-Fard S**. The emerging role of miR-20b in human cancer and other disorders: pathophysiology and therapeutic implications. *Frontiers in Oncology*, section Molecular and Cellular Oncology. 2022 [accepted].
94. **Ghafouri-Fard S**, Gholami L, Sadeghpour S, Nazer N, Hussen BM, Sayad A, Taheri M. Altered expression of SOCS genes periodontitis. *BMC oral Health*. 2022 [accepted].
95. ...**Ghafouri-Fard S**...Exosomal circular RNA: A signature for lung cancer progression. *Cancer Cell International*. 2022 [accepted].
96. **Ghafouri-Fard S**, Safarzadeh A, Hussen BM, Taheri M, Samsami M. A review on the role of ncRNAs in the pathogenesis of cholangiocarcinoma. *International Journal of Biological Macromolecules*. 2022 [accepted].
97. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Baniahmad A, Taheri M, Mokhtari M. A review on the role of PCGEM1 lncRNA in cancer. *Pathology Research and Practice*. 2022 [accepted].
98. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Baniahmad A, Taheri M, Hajiesmaeili M. A concise review on dysregulation of LINC00665 in cancers. *Cells*. 2022 [accepted].
99. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Baniahmad A, Taheri M, Samsami M. A review on the role of NR2F1-AS1 in the development of cancer. *Pathology Research and Practice*. 2022 [accepted].
100. **Ghafouri-Fard S**, Askari A, Hussen BM, Taheri M, Akbari Dilmaghani N. TMPO-AS1: a long non-coding RNA with important roles in the carcinogenesis. *Frontiers in Cell and Developmental Biology*, section Cancer Cell Biology. 2022 [accepted].
101. **Ghafouri-Fard S**, Safarzadeh A, Hussen BM, Taheri M, Rashnoo F. In silico characterization of competing endogenous RNA network in castration-resistant prostate cancer cells in presence of the natural compound atraric acid using RNA-seq analysis. *Pathology Research and Practice*. 2022 [accepted].
102. **Ghafouri-Fard S**,...A concise review on the role of LINC00324 in different cancers. *Pathology Research and Practice*. 2022 [accepted].

103. **Ghafouri-Fard S**, Poornajaf Y, Hussen BM, Shoorei H, Taheri M, Sharifi G. Interplay between programmed death-ligand 1 and non-coding RNAs. *Frontiers in Immunology, section Cancer Immunity and Immunotherapy*. 2022 [accepted].
104. Akbari M, Mohebi M, Berjis K, Ghahremani A, Modarresi MH, **Ghafouri-Fard S**. A novel variant in TLE6 is associated with embryonic developmental arrest (EDA) in familial female infertility. *Scientific Reports*. 2022 [accepted].
105. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Abdullah ST, Taheri M, Samadian M. A review on the role of miR-16-5p in the carcinogenesis. *Cancer Cell International*. 2022 [accepted].
106. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Dong P, Gassler N, Taheri M, Baniahmad A. A review on the role of cyclin dependent kinases in cancers. *Cancer Cell International*. 2022 [accepted].
107. **Ghafouri-Fard S**, Jamali E, Taheri M, Akbari Dilmaghani N. Role of lncRNAs and circRNAs in epilepsy. *Ageing Research Reviews*. 2022 [accepted].
108. ..., **Ghafouri-Fard S**. Strategies to Overcome the Main Challenges of the Use of Exosomes as Drug Carrier for Cancer Therapy. *Cancer Cell International*. 2022 [accepted].
109. ..., **Ghafouri-Fard S**, ... Antioxidant and Anti-apoptotic Effects of Selenium Nanoparticles and Lactobacillus Casei on Mice Testis after X-ray. *Andrologia*. 2022 [accepted].
110. **Ghafouri-Fard S**, Bahroudi Z, Shoorei H, Hussen BM, Talebi SF, Ghousia Baig S, Taheri M, Ayatollahi SA. The effects of resveratrol on expression of genes in diverse disorders with an especial focus on PI3K/AKT signaling pathway. *Cancer Cell International*. 2022 [accepted].
111. Alizadeh B, Alibabaei A, Ahmadi S, Maroufi SF, **Ghafouri-Fard S**, Nateghinia S. Designing Predictive Models for Appraisal of Outcome of Neurosurgery Patients Using Machine Learning-Based Techniques. *Interdisciplinary Neurosurgery*. 2022 [accepted].
112. Alijanpour S, Miryounesi M, **Ghafouri-Fard S**. The role of excitatory amino acid transporter 2 (EAAT2) in epilepsy and other neurological disorders. *Metabolic Brain Disorder*. 2022 [accepted].
113. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Taheri M, Samsami M. miR-1908: a microRNA with diverse functions in cancers and non-malignant conditions. *Cancer Cell International*. 2022 [accepted].
114. **Ghafouri-Fard S**, ... A review on the role of MEG8 lncRNA in human disorders. *Cancer Cell International*. 2022 [accepted].
115. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Taheri M, Samsami M. Emerging role of non-coding RNAs in the regulation of Sonic Hedgehog signaling pathway. *Cancer Cell International*. 2022 [accepted].

116. **Ghafouri-Fard S**, Shoorei H, Poornajaf Y, Hussen BM, Abak A, Taheri M, Eghbali A. NLRP3: Role in Ischemia/Reperfusion Injuries. *Frontiers in Immunology*, section Inflammation. 2022 [accepted].
117. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Taheri M, Ebrahimzadeh K, Noroozi R. The emerging role of lncRNAs, miRNAs, and an accelerated epigenetic age in Huntington's disease. *Frontiers in Aging Neuroscience*, section Cellular and Molecular Mechanisms of Brain-aging. 2022 [accepted].
118. Taheri M, Hussen BM, Najafi S, Abak A, **Ghafouri-Fard S**, Samsami M, Baniahmad A. Molecular mechanisms of Inhibitor of Growth (ING) family members in health and malignancy. *Cancer Cell International*. 2022 [accepted].
119. ... **Ghafouri-Fard S** ... Analysis of expression of regulatory T cell related lncRNAs in inflammatory demyelinating polyneuropathies. *International Immunopharmacology*. 2022 [accepted].
120. **Ghafouri-Fard S**, Poornajaf Y, Hussen BM, Abak A, Shoorei H, Taheri M, Sharifi G. Implication of Non-Coding RNA-mediated ROCK1 regulation in various diseases. *Frontiers in Molecular Biosciences*, section RNA Networks and Biology. 2022 [accepted].
121. Akbari M, Gholipour M, Davoudikianersi H, Hussen BM, Abak A, Eslami S, **Ghafouri-Fard S**, Sayad A. Expression of NF- κ B-associated lncRNAs in different types of migraine. *Acta Neurologica Belgica*. 2022 [accepted].
122. **Ghafouri-Fard S**, Shirvani-Farsani Z, Hussen BM, Taheri M, Samsami M. The key roles of non-coding RNAs in the pathophysiology of hypertension. *The European Journal of Pharmacology*. 2022 [accepted].
123. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Taheri M, Mokhtari M. A review on the role of LINC01133 in cancers. *Cancer Cell International*. 2022 [accepted].
124. Eghtedarian R, Akbari M, Badrlou E, Hussen BM, Eslami S, Akhavan-Bahabadi M, Taheri M, **Ghafouri-Fard S**, Neishabouri SM. Assessment of expression of oxytocin-related lncRNAs in schizophrenia. *The European Journal of Pharmacology*. 2022 [accepted].
125. **Ghafouri-Fard S**, Safarzadeh A, Akhavan-Bahabadi M, Hussen BM, Taheri M, Akbari Dilmaghani N. Expression pattern of non-coding RNAs in non-functioning pituitary adenoma. *Frontiers in Oncology*, section Molecular and Cellular Oncology. 2022 [accepted].
126. Taheri M, **Ghafouri-Fard S**, ... Hormonal regulation of telomerase activity and hTERT expression in steroid-regulated tissues and cancer. *Cancer Cell International*. 2022 [accepted].
127. **Ghafouri-Fard S**, Noie Alamdari A, Noee Alamdari Y, Abak A, Hussen BM, Taheri M, Jamali E. Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers. *Cancer Cell International*. 2022 [accepted].
128. Kadkhoda S, Eslami S, Hussen BM, **Ghafouri-Fard S**. A review on the importance of miRNA-135 in human diseases. *Frontiers in Genetics*, section RNA. 2022 [accepted].

129. Dadyar M, Hussen BM, Eslami S, Taheri M, Emadi F, **Ghafouri-Fard S**, Sayad A. Expression of T cell-related lncRNAs in multiple sclerosis, *Frontiers in Genetics*, section RNA. 2022 [accepted].
130. Kadkhoda S, **Ghafouri-Fard S**, Noorbakhsh F, Ravaei S, Darbeheshti F, Amoli MM, Taslimi R, Shakoori A. The Importance of Regulatory Pathway Mediated By Circ0001955 in Colorectal Cancer. *Experimental and Molecular Pathology*. 2022 [accepted].
131. Hussen BM, Kheder RK, Tharwat Abdullah S, Hidayat HJ, Rahman SH, Salihi A, Taheri M, **Ghafouri-Fard S**. Functional interplay between long non-coding RNAs and Breast CSCs. *Cancer Cell International*. 2022 [accepted].
132. Jamali E, Khoshbakht T, Taheri M, **Ghafouri-Fard S**, Baniahmad A. A review on the role of PRNCR1 in human disorders. *Pathology Research and Practice*. 2022 [accepted].
133. Roustai-Geraylow K, Hemmati R, Kakhoda S, **Ghafouri-Fard S**. miRNA expression in COVID-19. *Gene Reports*. 2022 [accepted].
134., **Ghafouri-Fard S**,... A dielectrophoresis-based microfluidic system having double-sided optimized 3D electrodes for label-free cancer cell separation with preserving cell viability. 2022 [accepted].
135. **Ghafouri-Fard S**, Gholami L, Nazer N, Hussen BM, Sayad A, Hajiesmaeili M. Down-regulation of oxytocin-related genes in periodontitis. *Frontiers in Molecular Neuroscience*, section Molecular Signalling and Pathways. 2022 [accepted].
136. Pourtavakoli A, **Ghafouri-Fard S**. Calcium signaling in neurodevelopment and pathophysiology of autism spectrum disorders. *Molecular Biology Reports*. 2022 [accepted].
137. Kadkhoda S, Hussen BM, **Ghafouri-Fard S**. A review on the Role of miRNA-324 in various diseases. *Frontiers in Genetics*, section RNA. 2022 [accepted].
138. Hussen BM, Hidayat HJ, **Ghafouri-Fard S**. Identification of expression of CCND1-related lncRNAs in breast cancer. *Pathology Research and Practice*. 2022 [accepted].
139. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Taheri M and Samadian M. A review on the role of MCM3AP-AS1 in the carcinogenesis and tumor progression. *Cancer Cell International*. 2022 [accepted].
140. **Ghafouri-Fard S**, Taheri M, Baniahmad A. Inhibitor of Growth Factors Regulate Cellular Senescence. *Cancers*. 2022 [accepted].
141., **Ghafouri-Fard S**. Expression analysis of CDKN2C-related lncRNAs in breast cancer. *Human Gene*. 2022 [accepted].
142. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Baniahmad A, Branicki W, Taheri M. Emerging role of non-coding RNAs in senescence. *Frontiers in Cell and Developmental Biology*, section Epigenomics and Epigenetics. 2022 [accepted].

143. **Ghafouri-Fard S**, Dashti S, Gholami L, Badrlou E, Sadeghpour S, Hussen BM, Jamal Hidayat H, Nazer N, Shadnoush M, Sayad A. Expression analysis of Wnt signaling pathway related lncRNAs in periodontitis: a pilot case-control study. *Human Gene*. 2022 [accepted].
144., **Ghafouri-Fard S**,Recent Advances and Challenges in Graphene-Based Nanocomposite Scaffolds for Tissue Engineering Application. *Journal of Biomedical Materials Research: Part A*. 2022 [accepted].
145. Akbari M, Eghtedarian R, Hussen BM, Eslami S, Taheri M, Neishabouri SM, **Ghafouri-Fard S**. Assessment of expression of regulatory T cell differentiation genes in autism spectrum disorder. *Frontiers in Molecular Neuroscience, section Molecular Signalling and Pathways*. 2022 [accepted].
146. Saleh Gargari S, Rahmati N, Fateh R, Khandani A, Nikfar S, **Ghafouri-Fard S**. Investigation of maternal and perinatal outcome in a population of Iranian pregnant women infected with COVID-19. *Scientific Reports*. 2022 [accepted].
147. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Sarfaraz S, Taheri M, Ayatollahi SA. Circ_CDR1as: a circular RNA with roles in the carcinogenesis. *Pathology Research and Practice*. 2022 [accepted].
148. Ousati Ashtiani Z, ..., **Ghafouri-Fard S**. Overexpression of long intergenic noncoding RNAs in bladder cancer: A new insight to cancer diagnosis. *Pathology Research and Practice*. 2022 [accepted].
149. Akbari M, Eghtedarian R, Hussen BM, Eslami S, Taheri M, **Ghafouri-Fard S**. Angiotensin I converting enzyme gene polymorphisms and risk of psychiatric disorders. *BMC Psychiatry*. 2022 [accepted].
150. Akbari M, Eshghyar F, Gholipour M, Eslami S, Hussen BM, Taheri M, Omrani MD, **Ghafouri-Fard S**. Expression analysis of mTOR-associated lncRNAs in multiple sclerosis. *Metabolic Brain Disease*. 2022 [accepted].
151. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Baniahmad A, Taheri M, Samadian M. A review on the role of DANCR in the carcinogenesis. *Cancer Cell International*. 2022 [accepted].
152. **Ghafouri-Fard S**, Hussen BM, Shaterabadi D, Abak A, Shoorei H, Taheri M, Rakhshan A. The interaction between human papilloma viruses related cancers and non-coding RNAs. *Pathology Research and Practice*. 2022 [accepted].
153. **Ghafouri-Fard S**, Hussen BM, Ganjo AR, Jamali E, Vafae R. A concise review on the interaction between genes expression/polymorphisms and exercise. *Human Gene*. 2022 [accepted].
154. Akbari M, Badrlou E, Eslami S, Hussen BM, Taheri M, Neishabouri SM, **Ghafouri-Fard S**. Association between angiotensin I converting enzyme gene polymorphisms and risk of autism in Iranian population. *Human Gene*. 2022 [accepted].
155. Younesi S, Yazdani B, Taheri Amin MM, Saadati P, Jamali S, Modarresi MH, Savad S, Amidi S, Razavi H, **Ghafouri-Fard S**. Incorporation Of Second-tier Tests And Secondary Biomarkers To Improve Positive Predictive Value (PPV) Rate In Newborn Metabolic Screening Program. *Journal of Clinical Laboratory Analysis*. 2022 [accepted].

156. **Ghafouri-Fard S**, Abak A, Baniahmad A, Hussen BM, Taheri M, Jamali E, Dinger ME. Interaction between non-coding RNAs, mRNAs and G-quadruplexes. *Cancer Cell International*. 2022 [accepted].
157. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Taheri M, Samsami M. Emerging role of circular RNAs in the pathogenesis of ovarian cancer. *Cancer Cell International*. 2022 [accepted].
158. Taheri M, Khoshbakht T, Hussen BM, Tharwat Abdullah S, **Ghafouri-Fard S**, Sayad A. The Emerging Role of microRNA in Periodontitis: Pathophysiology, Clinical Potential and Future Molecular Perspectives. *Current Stem Cell Research & Therapy*. 2022 [accepted].
159. Fathi M, Asadzadeh Aghdaie H, **Ghafouri-Fard S**, Shams R. Evaluation of potential of miR-8073 and miR-642 as diagnostic markers in pancreatic cancer. *Molecular Biology Reports*. 2022 [accepted].
160. **Ghafouri-Fard S**, Khanbabapour Sasi A, Hussen BM, Shoorei H, Siddiq A, Taheri M, Ayatollahi SA. Interplay Between PI3K/AKT Pathway and Heart Disorders. *Molecular Biology Reports*. 2022 [accepted].
161. Rahmani S, Kadkhoda S, **Ghafouri-Fard S**. Synaptic plasticity and depression: the role of miRNAs dysregulation. *Molecular Biology Reports*. 2022 [accepted].
162. Maloum Z, Ramezani S, Taheri M, Shirvani-Farsani Z, **Ghafouri-Fard S**. Downregulation of Long Non-Coding RNAs in patients with bipolar disorder. *Scientific Reports*. 2022 [accepted].
163. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Hidayat H, Taheri M, Hajiesmaeili M. A comprehensive review on function of miR-15b-5p in malignant and non-malignant disorders. *Frontiers in Oncology, section Cancer Genetics*. 2022 [accepted].
164. **Ghafouri-Fard S**, Poornajaf Y, Dashti F, Hussen BM, Taheri M, Jamali E. Interaction between non-coding RNAs and Interferons: with an especial focus on type I interferons. *Frontiers in Immunology, section Cytokines and Soluble Mediators in Immunity*. 2022 [accepted].
165. Maloum Z, Ramezani S, Taheri M, Shirvani-Farsani Z, **Ghafouri-Fard S**. Significant Reduction of Long Non-Coding RNAs Expression in Bipolar Disorder. *BMC Psychiatry*. 2022 [accepted].
166. **Ghafouri-Fard S**, ... A review on the role of PTENP1 in human disorders with an especial focus on tumor suppressor role of this lncRNA. *Cancer Cell International*. 2022 [accepted].
167. Gholipour M, Honarmand Tamizkar K, Niknam A, Hussen BM, Eslami S, Sayad A, **Ghafouri-Fard S**. Expression analysis of vitamin D receptor and its related long non-coding RNAs in peripheral blood of patients with Parkinson's disease. *Molecular Biology Reports*. 2022 [accepted].
168. Akbari M, Akhavan-Bahabadi M, Shafiq N, Taheriazamd A, Hussen BM, Sayad A, Fathi M, Taheri M, **Ghafouri-Fard S**, Fathi M. Expression analysis of IFNAR1 and TYK2 transcripts in COVID-19 patients. *Cytokine*. 2022 [accepted].
169. **Ghafouri-Fard S**, Hussen BM, Pashmforoush S, Akbari MT, Arsang-Jang S, Nazer N, Hamidieh AA, Hajifathali A, Dinger ME, Sayad A, Ostadali Dehaghi M. HLA alleles and haplotype frequencies in Iranian population. *Humam Antibodies*. 2022 [accepted].

170. Sayad A, Najafi S, Hussien BM, Jamali E, Taheri M, **Ghafouri-Fard S**. The role of circular RNAs in pancreatic cancer; new players in tumorigenesis and potential biomarkers. *Pathology-Research & Practice*. 2022 [accepted].
171. Moallemi L, Yumashev AV, Hussien BM, Hidayat H, **Ghafouri-Fard S**, Taheri M, Niazi V, Hajiesmaeili M. Therapeutic potential of microvesicles in cell therapy and regenerative medicine of ocular diseases with an especial focus on mesenchymal stem cells-derived microvesicles. *Frontiers in Genetics, section RNA*. 2022 [accepted].
172. Eghtedarian R, **Ghafouri-Fard S**, Bouraghi H, Hussien BM, Arsang-Jang S, Taheri M. Abnormal pattern of vitamin D receptor-associated genes and lncRNAs in patients with bipolar disorder. *BMC Psychiatry*. 2022 [accepted].
173. **Ghafouri-Fard S**, Hussien BM, Mohaqiq M, Shoorei H, Baniahmad A, Taheri M, Arefian N. Interaction between non-coding RNAs and Programmed Cell Death Proteins. *Frontiers in Oncology, section Cancer Molecular Targets and Therapeutics*. 2022 [accepted].
174. Kakhoda S, **Ghafouri-Fard S**. The Importance of miRNA-630 in Human Diseases with an especial focus on cancers. *Cancer Cell International*. 2022 [accepted].
175. Akbari M, Gholipour M, Hussien BM, Taheri M, Eslami S, Sayad A, **Ghafouri-Fard S**. Expression of BDNF-Associated lncRNAs in Parkinson's Disease. *Metabolic Barin Disease*. 2022 [accepted].
176., **Ghafouri-Fard S**,... Intracranial Rosai Dorfman Disease presenting with multiple huge intraventricular masses, a case report. *Frontiers in Surgery, section Neurosurgery*. 2022 [accepted].
177. **Ghafouri-Fard S**, Majidpoor J, Shoorei H, Mahmud Hussien B, Hidayat H, Baniahmad A, Taheri M, Mokhtari M. The Interaction Between Non-coding RNAs and Calcium Binding Proteins. *Frontiers in Oncology, section Molecular and Cellular Oncology*. 2022 [accepted].
178. **Ghafouri-Fard S**,..., Taheri M. The emerging role non-coding RNAs in B cell-related disorders. *Cancer Cell International*. 2022 [accepted].
179. **Ghafouri-Fard S**, Khoshbakht T, Hussien BM, Baniahmad A, Taheri M, Rashnoo F. A review on the role of PCA3 lncRNA in carcinogenesis with an especial focus on prostate cancer. *Pathology-Research and Practice*. 2022 [accepted].
180. **Ghafouri-Fard S**, Najafi S, Taheri M, Samadian M. DLX6-AS1: A long non-coding RNA with oncogenic features. *Frontiers in Cell and Developmental Biology, section Molecular and Cellular Oncology*. 2022 [accepted].
181. **Ghafouri-Fard S**, Najafi S, Mahmud Hussien B, Basiri A, Hidayat H, Taheri M, Rashnoo F. The Role of circular RNAs in the Carcinogenesis of Bladder Cancer. *Frontiers in Oncology, section Genitourinary Oncology*. 2022 [accepted].

182. **Ghafouri-Fard S**, Shirvani-Farsani Z, Mahmud Hussen B, Taheri M, Jalili Khoshnoud R. Emerging role of non-coding RNAs in the regulation of KRAS. *Cancer Cell International*. 2022 [accepted].
183. Kakhoda S, **Ghafouri-Fard S**. Function of miRNA-145-5p in the pathogenesis of human disorders. *Pathology - Research and Practice*. 2022 [accepted].
184. **Ghafouri-Fard S**,...Aberrant expression of miRNAs in epilepsy. *Molecular Biology Reports*. 2022 [accepted].
185. Hasani B,..., **Ghafouri-Fard S**. Constructing mRNA, miRNA, circRNA and lncRNA Regulatory Network by Analysis of microarray data in Breast Cancer. *Gene Reports*. 2022 [accepted].
- 186...., **Ghafoueri-Fard S**. Signaling pathways modulated by miRNAs in breast cancer angiogenesis and new therapeutics. *Pathology - Research and Practice*. 2022 [accepted].
- 187....**Ghafouri-Fard S**,...The Emerging Roles of NGS in Clinical Oncology and Personalized Medicine. *Pathology - Research and Practice*. 2022 [accepted].
188. **Ghafouri-Fard S**, Khoshbakht T, Hussen BM, Kadkhda S, Taheri M, Tafrishinejad A. A review on the role of miR-149-5p in the carcinogenesis. *International Journal of Molecular Sciences*. 2021 [accepted].
189. **Ghafouri-Fard S**, Hussen BM, Hadayat Jamal H, Taheri M, Sharifi G. The emerging role of non-coding RNAs in the regulation of virus replication and resultant cellular pathologies. *International Journal of Molecular Sciences*. 2021 [accepted].
- 190.... **Ghafouri-Fard S**,...Strategies to Overcome the Main Challenges of the Use of CRISPR/Cas9 as a Replacement for Cancer Therapy. *Molecular Cancer*. 2021 [accepted].
191. **Ghafouri-Fard S**, Shoorei H, Bahroudi Z, Hussen BM, Talebi SF, Taheri M, Ayatollahi SA. Nrf2-Related Therapeutic Effects of Curcumin in Different Disorders. *Biomolecules*. 2021 [accepted].
192. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Shojaei S. A review on the role of SPRY4-IT1 in the carcinogenesis. *Frontiers in Oncology, section Molecular and Cellular Oncology*. 2021 [accepted].
193. **Ghafouri-Fard S**, Mahmud Hussen B, Abak A, Taheri M, Ayatollahi SA. Emerging role of non-coding RNAs in the course of HIV infection. *Internatiional Immunopharmacology*. 2021 [accepted].
194. Najafi S, **Ghafouri-Fard S**, Mahmud Hussen B, Hidayat H, Taheri M, Hallajnejad M. Oncogenic Roles of Small Nucleolar RNA Host Gene 7 (SNHG7) Long Non-coding RNA in Human Cancers and Potentials. *Frontiers in Cell and Developmental Biology, section Molecular and Cellular Oncology*. 2021 [accepted].
195. Eslami S, Glassy MC, **Ghafouri-Fard S**. A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. *Gene*. 2021 [accepted].
196. Varmazyari V, Ghafoorifard H, Habibiyan H, Ebrahimi M, **Ghafouri-Fard S**. A microfluidic device for label-free separation sensitivity enhancement of circulating tumor cells of various and similar size. *Journal of Molecular Liquids*. 2021 [accepted].

197. **Ghafouri-Fard S**, Azimi T, Mahmud Hussen B, Taheri M, Jalili Khoshnoud R. A review on the role of non-coding RNAs in the pathogenesis of myasthenia gravis. *International Journal of Molecular Sciences*. 2021 [accepted].
198. **Ghafouri-Fard S**, Abak A, Mahmud Hussen B, Taheri M, Sharifi G. The emerging role of non-coding RNAs in pituitary gland tumors and meningioma. *Cancers*. 2021 [accepted].
- 199....**Ghafouri-Fard S**. Circular RNAs in Renal Cell Carcinoma: Functions in Tumorigenesis and Diagnostic and Prognostic Potentials. *Pathology - Research and Practice*. 2021 [accepted].
200. **Ghafouri-Fard S**,... Assessment of expression of NF- κ B-related genes in periodontitis. *Gene Reports*. 2021 [accepted].
201. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Samadian M. A review on the role of miR-1290 in cell proliferation, apoptosis and invasion. *Frontiers in Molecular Biosciences, section RNA Networks and Biology*. 2021 [accepted].
202. Sabaie H, Salkhordeh Z, Asadi MR, **Ghafouri-Fard S**, Amirinejad N, Askarinejad Behzadi M, Taheri M, Rezazadeh M. Long non-coding RNA- associated competing endogenous RNA axes in T-cells in multiple sclerosis. *Frontiers in Immunology, section Multiple Sclerosis and Neuroimmunology*. 2021 [accepted].
203. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Samadian M. A review on the role of miR-1246 in the pathoetiology of different cancers. *Frontiers in Molecular Biosciences, section RNA Networks and Biology*. 2021 [accepted].
204. **Ghafouri-Fard S**, Khoshbakht T, Mahmud Hussen B, Taheri M, Arefian N. Alterations in non-coding RNAs during sepsis. *Frontiers in Immunology, section Microbial Immunology*. 2021 [accepted].
205. **Ghafouri-Fard S**, ... Transcript levels of cytokine coding genes in peripheral blood and tissues of patients with periodontitis. *Human Antibodies*. 2021 [accepted].
206. Taheri M, Khoshbakht T, Jamali E, Kallenbach J, **Ghafouri-Fard S**, Aria Baniahmad. Interaction between non-coding RNAs and androgen receptor with an especial focus on prostate cancer. *Cells*. 2021 [accepted].
207. **Ghafouri-Fard S**, Poulet C, Malaise M, Abak A, Taheri M, Taheriazam A. The emerging role of non-coding RNAs in osteoarthritis. *Frontiers in Immunology, section Autoimmune and Autoinflammatory Disorders*. 2021 [accepted].
208. **Ghafouri-Fard S**, Fathi M, Zhai T, Taheri M, Dong P. LncRNAs: novel biomarkers for pancreatic cancer. *Biomolecules*. 2021 [accepted].
- 209....**Ghafouri-Fard S**. Assessment of expression of a number of immune-related genes in the periodontitis. *Ecological Genetics and Genomics*. 2021 [accepted].

210. **Ghafouri-Fard S**, Khoshbakht T, Taheri M. A review on the role of AFAP1-AS1 in the pathoetiology of cancer. *Frontiers in Oncology, section Molecular and Cellular Oncology*. 2021 [accepted].
211. Jalaiei A, Asadi MR, Sabaie H, Dehghani H, Gharesouran J, Taheri M, **Ghafouri-Fard S**, Maryam Rezazadeh Long non-coding RNAs (LncRNAs), novel offenders or guardians in multiple sclerosis: a scoping review. *Frontiers in Immunology, section Multiple Sclerosis and Neuroimmunology*. 2021 [accepted].
- 212.... **Ghafouri-Fard S**. COVID-19 pandemic: Insights into genetic susceptibility to SARS-CoV-2 and host genes implications on virus spread, disease severity and outcomes. *Human Antibodies*. 2021 [accepted].
213. Talebi F, Ghafourifard H, **Ghafouri-Fard S**, Jahanshahi A. A straight-forward, inexpensive, low power continuous-flow μ PCR chip using PCB-based heater electrodes with uniform temperature distribution. *Sensors and Actuators: A. Physical*. 2021 [accepted].
214. Akbari M, Taheri M, Mehrpoor G, Eslami S, Mahmud Hussen B, **Ghafouri-Fard S**, Arefian N. Assessment of ACE1 variants and ACE1/ACE2 expression in COVID-19 patients. *Vascular Pharmacology*. 2021 [accepted].
- 215.... **Ghafouri-Fard S**... Hypoxia preconditioned mesenchymal stem cell-derived exosomes induce ex vivo expansion of umbilical cord blood hematopoietic stem cells CD133+ by stimulation of Notch signalling pathway, *Biotechnology Progress*. 2021 [accepted].
216. **Ghafouri-Fard S**,... Association between genetic variants and risk of obsessive-compulsive disorder. *Metabolic Brain Disease*. 2021 [accepted].
217. Samsami M, Fatemi A, Jalili Khoshnoud R, Kohansal K, Mahmud Hussen B, Soghala S, Taheri M, **Ghafouri-Fard S**. Abnormal transcript levels of cytokines among Iranian COVID-19 patients. *Journal of Molecular Neuroscience*. 2021 [accepted].
218. **Ghafouri-Fard S**, Gholipour M, Abak A, Mahmud Hussen B, Kholghi Oskoei V, Taheri M, Rakhshan. Association analysis of MALAT1 polymorphisms and risk of psoriasis among Iranian patients. *International Journal of Immunogenetics*. 2021 [accepted].
219. **Ghafouri-Fard S**, Shirvani Farsani Z, Mahmud Hussen B, Taheri M, Arefian N. Emerging impact of non-coding RNAs in the pathology of stroke. *Frontiers in Aging Neuroscience*. 2021 [accepted].
220. Honarmand Tamizkar K, Gorji P, Gholipour M, Mazdeh M, Eslami S, Taheri M, **Ghafouri-Fard S**. Parkinson's disease is associated with dysregulation of circulatory levels of lncRNAs. *Frontiers in Immunology, section Multiple Sclerosis and Neuroimmunology*. 2021 [accepted].
221. Taherii M, Kargl J, Andreas Barth D, Rezaei O, **Ghafouri-Fard S**, Pichler M. Emerging role of non-coding RNAs in regulation of T-lymphocyte function. *Frontiers in Immunology, section Cytokines and Soluble Mediators in Immunity*. 2021 [accepted].

222. Taheri M, Najafi S, Abak A, Basiri A, Baniahmad A, Jamali E, **Ghafouri-Fard S**. The Role and Clinical Potentials of Circular RNAs in Prostate Cancer. *Frontiers in Oncology*, section Genitourinary Oncology. 2021 [accepted].
223. **Ghafouri-Fard S**, Khanbabapour Sasi A, Abak A, Shoorei H, Khoshkar A, Taheri M. Contribution of miRNAs in the pathogenesis of breast cancer. *Frontiers in Oncology*, section Cancer Genetics. 2021 [accepted].
224. **Ghafouri-Fard S**,... Emerging role of non-coding RNAs in autism spectrum disorder. *Journal of Molecular Neuroscience*. 2021 [accepted].
225. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Jamali E. A concise review on the role of circPVT1 in tumorigenesis, drug sensitivity and cancer prognosis. *Frontiers in Oncology*, section Cancer Genetics. 2021 [accepted].
226. Mahmud Hussien B, Tharwat Abdullah S, Fatih Rasul M, Salihi A, **Ghafouri-Fard S**, Jamal Hidayat H, Taheri M. MicroRNA: An important player in breast cancer angiogenesis and therapeutic targets. *Frontiers in Molecular Biosciences*, section Protein and RNA Networks. 2021 [accepted].
227. Molaei Ramshe S, Ghaedi H, Omrani MD, Geranpayeh L, Alipour B, **Ghafouri-Fard S**. Up-regulation of FOXP3-AS1 in invasive ductal carcinoma of breast cancer patients. *Heliyon*. 2021 [accepted].
228. Yazarlou F, Kadkhoda S, **Ghafouri-Fard S**. Emerging role of let-7 family in the pathogenesis of hematological malignancies. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
229. **Ghafouri-Fard S**, Mohammad-Rahimi H, Motie P, Minabi MAS, Taheri M, Nateghinia S. Application of machine learning in the prediction of COVID-19 daily new cases: A Scoping Review. *Heliyon*. 2021 [accepted].
230. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Jamali E. CircITCH: a circular RNA with eminent roles in the carcinogenesis. *Frontiers in Oncology*, section Molecular and Cellular Oncology. 2021 [accepted].
231. **Ghafouri-Fard S**,... Expression of VDR-related lncRNAs in malignancies originated from salivary gland: a pilot study. *Meta Gene*. 2021 [accepted].
232. **Ghafouri-Fard S**, Honarmand Tamizkar K, Taheri M, Ayatollahi SA. Contribution of circRNAs in gastric cancer. *Pathology - Research and Practice*. 2021 [accepted].
233. **Ghafouri-Fard S**, Gholipour M, Abak A, Mazdeh M, Taheri M, Sayad A. Expression analysis of NF- κ B-related lncRNAs in Parkinson's disease. *Frontiers in Immunology*, section Multiple Sclerosis and Neuroimmunology. 2021 [accepted].
234. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Ebrahimzadeh K. A review on the carcinogenic roles of DSCAM-AS1. *Frontiers in Cell and Developmental Biology*, section Molecular and Cellular Oncology. 2021 [accepted].

235. **Ghafouri-Fard S**, Gholami L, Badrlou E, Sadeghpour S, Nazer N, Shadnoush M, Sayad A, Taheri M. Dysregulation of lncRNAs in circulation of patients with periodontitis: results of a pilot study. *BMC Oral Health*. 2021 [accepted].
236. Mokhtari S, Atarbashi-Moghadam S, Motevaseli E, Hesampour A, **Ghafouri-Fard S**. *Lactobacillus Fermentum* and *Lactobacillus Crispatus* do not have cytotoxic effects on HN5 Oral Squamous Cell Carcinoma Cell Line. *International Journal of Dentistry*. 2021 [accepted].
237. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Kashefzadeh A. Hepatocyte nuclear factor 1A-antisense: review of its role in the carcinogenesis. *Pathology - Research and Practice*. 2021 [accepted].
238. **Ghafouri-Fard S**, Azimi T, Taheri M. A comprehensive review on the role of genetic factors in neuromyelitis optica spectrum disorder. *Frontiers in Immunology, section Multiple Sclerosis and Neuroimmunology*. 2021 [accepted].
239. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Shojaei S. A review on the role of SNHG16 lncRNA in the carcinogenic processes. *Frontiers in Cell and Developmental Biology, section Molecular and Cellular Oncology*. 2021 [accepted].
240. **Ghafouri-Fard S**, Honarmand Tamizkar K, Sayad A, Taheri M, Samadian M. Expression analysis of SOCS genes in migraine. *Frontiers in Molecular Neuroscience, section Pain Mechanisms and Modulators*. 2021 [accepted].
241. Honarmand Tamizkar K, Badrlou E, Aslani T, Brand S, Arsang-Jang S, **Ghafouri-Fard S**, Taheri M. Dysregulation of NF- κ B-associated lncRNAs in autism spectrum disorder. *Frontiers in Molecular Neuroscience, section Brain Disease Mechanisms*. 2021 [accepted].
242. Younesi S, Taheri Amin MM, Hantoushzadeh S, Saadati P, Jamali S, Modarresi MH, Savad S, Delshad S, Amidi S, Geranorimi T, Navidpour F, **Ghafouri-Fard S**. Karyotype analysis of amniotic fluid cells and report of chromosomal abnormalities in 15401 cases of Iranian women. *Scientific Reports*. 2021 [accepted].
243. Kadkhoda S, Taslim R, Noorbakhsh F, Darbeheshi F, Tavakkoly Bazzaz J, **Ghafouri-Fard S**, Shakoori A. Importance of Circ0009910 in Colorectal Cancer Pathogenesis as a Possible Regulator of miR-145 and PEAK1. *World Journal of Surgical Oncology*. 2021 [accepted].
244. **Ghafouri-Fard S**, Abak A, Talebi SF, Shoorei H, Taheri M, Akbari Dilmaghani. Role of miRNA and lncRNAs in Organ Fibrosis and Aging. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
245. Asadi MR, Rahmanpour D, Moslehian MS, Sabaie H, Hassani M, **Ghafouri-Fard S**, Taheri M, Rezazadeh M. Stress Granules involved in Formation, progression and metastasis of cancer: a scoping review. *Frontiers in Cell and Developmental Biology, section Molecular and Cellular Oncology*. 2021 [accepted].
246. **Ghafouri-Fard S**, Abak A, Tavakkoli Avval S, Shoorei H, Taheri M, Samadian M. The impact of non-coding RNAs on macrophage polarization. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
247. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Mokhtari M. A review on the role of GAS6 and GAS6-AS1 in the carcinogenesis. *Pathology - Research and Practice*. 2021 [accepted].

248. **Ghafouri-Fard S**, Honarmand Tamizkar K, Gholipour M, Abak A, Kholghi Oskooei V, Taheri M, Rakhshan A. Association analysis of GAS5 polymorphisms and psoriasis. *Gene Reportes*. 2021 [accepted].
249. **Ghafouri-Fard S**, Eghtedarian R, Seyedi M, Pouresmaeili F, Arsang-Jang S, Taheri M. Up-regulation of VDR-associated lncRNAs in schizophrenia. *Journal of Molecular Neuroscience*. 2021 [accepted].
250. **Ghafouri-Fard S**, Akbari MT, Mazdeh M, Nazer N, Rezaei O, Taheri M, Sayad A. Distribution of HLA alleles and genotypes in patients with chronic inflammatory demyelinating polyneuropathy. *Journal of Molecular Neuroscience*. 2021 [accepted].
251. Asadi MR, Hassani M, Kiani S, Sabaie H, Moslehian MS, Kazemi M, **Ghafouri-Fard S**, Taheri M, Rezazadeh M. The perspective of dysregulated lncRNAs in Alzheimer's disease: a systematic scoping review. *Frontiers in Aging Neuroscience*. 2021 [accepted]
252. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Ghanbari M. A concise review on the role of BDNF-AS in human disorders. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
253. **Ghafouri-Fard S**, Behzad Moghadam MH, Shoorei H, Bahroudi Z, Taheri M, Taheriazam A. The impact of non-coding RNAs on normal stem cells. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
254. **Ghafouri-Fard S**, Safari M, Taheri M, Samadian M. Expression of linear and circular lncRNAs in Alzheimer's disease. *Journal of Molecular Neuroscience*. 2021 [accepted].
255. Miladipour A, Gholipour M, Honarmand Tamizkar K, Abak A, Kholghi V, Taheri M, **Ghafouri-Fard S**. Investigation of FADS Gene Cluster Single Nucleotide Polymorphisms in End Stage Renal Disease Compared with Normal Controls. *Frontiers in Genetics, section Applied Genetic Epidemiology*. 2021 [accepted].
256. **Ghafouri-Fard S**, Shoorei H, Abak A, Seify M, Mohaqiq M, Keshmir F, Taheri M, Ayatollahi SA. Effects of chemotherapeutic agents on male germ cells and possible ameliorating impact of antioxidants. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
257. **Ghafouri-Fard S**, Khoshbakht T, Bahranian A, Taheri M. CircMTO1: a circular RNA with roles in the carcinogenesis. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
258. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Ebrahimzadeh K. A review on the role of PCAT6 lncRNA in tumorigenesis. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
259. **Ghafouri-Fard S**, Kamali MJ, Abak A, Shoorei H, Majidpoor J, Taheri M. lncRNA ZFAS1: role in tumorigenesis and other diseases. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
260. **Ghafouri-Fard S**, Azimi T, Taheri M. Cervical carcinoma high expressed 1 (CCHE1): an oncogenic lncRNA in diverse neoplasms. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
261. Gholipour M, Taheri M, Mehvari Habibabadi J, Nazer N, Sayad A, **Ghafouri-Fard S**. Dysregulation of lncRNAs in autoimmune neuropathies. *Scientific Reports*. 2021 [accepted].

262. **Ghafouri-Fard S**, Atarbashi-Moghadam S, Kholghi-Oskooei V, Ashrafi Hafez A, Taheri M. Expression of VDR-related lncRNAs in malignancies originated from salivary gland. *Gene Reports*. 2021 [accepted].
263. **Ghafouri-Fard S**, Azimi T, Hussen BM, Abak A, Taheri M, Dilmaghani A. Non-coding RNA activated by DNA damage (NORAD): review of its roles in the carcinogenesis. *Frontiers in Cell and Developmental Biology*, section Molecular and Cellular Oncology. 2021 [accepted].
264. Atarbashi-Moghadam S, Vafadar S, Shafagh S, Kholghi-Oskooei V, **Ghafouri-Fard S**, Taheri M. Expression of lncRNAs in salivary gland malignancies. *Gene Reports*. 2021 [accepted].
265. **Ghafouri-Fard S**, Khoshbakht T, Taheri M, Hajiesmaeili M. Long Intergenic Non-Protein Coding RNA 460: Review of its Role in Carcinogenesis. *Pathology-Research and Practice*. 2021 [accepted].
266. **Ghafouri-Fard S**, Abak A, Tavakkoli Avval S, Rahmani S, Shoorei H, Taheri M, Samadian M. Contribution of miRNAs and lncRNAs in osteogenesis and related disorders. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
267. **Ghafouri-Fard S**, Agabalazadeh A, Shoorei H, Majidpoor J, Taheri M, Mokhtari M. The impact of lncRNAs and miRNAs on apoptosis in lung cancer. *Frontiers in Oncology*, section Cancer Genetics. 2021 [accepted].
268. **Ghafouri-Fard S**, Hajiesmaeili M, Shoorei H, Bahroudi Z, Taheri M, Sharifi G. The impact of lncRNAs and miRNAs in regulation of function of cancer stem cells and progression of cancer. *Frontiers in Cell and Developmental Biology*, section Stem Cell Research. 2021 [accepted].
269. Fathi M, ..., **Ghafouri-Fard S**. Emerging roles of miRNAs in the development of pancreatic cancer. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
270. **Ghafouri-Fard S**, Hussen, B.M., Badrlou, E., Abak, A., Taheri, M. MicroRNAs as important contributors in the pathogenesis of colorectal cancer. *Biomedicine and Pharmacotherapy*, 2021, 140, 111759
271. Taheri M, Sangseifid S, Shahani P, Eftekharian MM, Arsang-Jang S, **Ghafouri-Fard S**. Assessment of expression of SOCS genes in acquired immune-mediated polyneuropathies. *Frontiers in Immunology*, section Autoimmune and Autoinflammatory Disorders. 2021 [accepted].
272. **Ghafouri-Fard S**, Shahir M, Salimi A, Taheri M. A review on the role of chemokines in the pathogenesis of systemic lupus erythematosus. *Cytokine*. 2021 [accepted].
273. Hussen BM, Azimi T, Abak A, Hidayat HJ, Taheri M, **Ghafouri-Fard S**. Role of lncRNA BANCR in human cancers: an updated review. *Frontiers in Cell and Developmental Biology*, section Molecular and Cellular Oncology. 2021 [accepted].
274. **Ghafouri-Fard S**, Shoorei H, Khanbabapour Sasi A, Taheri M, Seyed Ayatollahi SA. The impact of the phytotherapeutic agent Quercetin on expression of genes and activity of signaling pathways. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
275. **Ghafouri-Fard S**, Asadi M, Sohrabi B, Arsang-Jang S, Mehravaran E, Taheri M, Samsami M. Down-regulation of a panel of immune-related lncRNAs in breast cancer. *Pathology-Research and Practice*. 2021 [accepted].

276. **Ghafouri-Fard S**, Abak A, Khademi S, Shoorei H, Bahroudi Z, Taheri M, Akbari Dilmaghani N. Functional Roles of Non-coding RNAs in Atrophy. *Biomedicine and pharmacotherapy*. 2021, 141, 111820.
277. **Ghafouri-Fard S**, Niazi V, Hussen BM, Omrani MD, Taheri M, Basiri A. The emerging role of exosomes in the treatment of human disorders with a special focus on mesenchymal stem cells-derived exosomes. *Frontiers in Cell and Developmental Biology*, section Stem Cell Research. 2021 [accepted].
278. **Ghafouri-Fard S**, Dinger ME, Maleki P, Taheri M, Hajiesmaeili M. Emerging role of circular RNAs in the pathobiology of lung cancer. *Biomedicine and pharmacotherapy*. 2021, 141, 111805.
279. Azimi T, **Ghafouri-Fard S**, Badrlou E, Omrani MD, Nazer N, Sayad A, Taheri M. Abnormal expression of NF- κ B-related transcripts in blood of patients with inflammatory peripheral nerve disorders. *Metabolic Brain Disease*. 2021 [accepted].
280. Taheri M, Moallemi Rad I, Hussen BM, Nicknafs F, Sayad A, **Ghafouri-Fard S**. Evaluation of expression of VDR-associated lncRNAs in COVID-19 patients. *BMC infections Diseases*. 2021 2021, 21(1), 588.
281. **Ghafouri-Fard S**, Abak A, Shoorei H, Talebi SF, Mohaqiq M, Taheri M, Mokhtari M. Interaction between non-coding RNAs and toll like receptors. *Biomedicine and pharmacotherapy*. 2021 140, 111784.
282. Nicknafs F, **Ghafouri-Fard S**, Omrani MD, Nazer N, Sayad A, Taheri M. Expression analysis of cytokine transcripts in inflammatory demyelinating polyradiculoneuropathy. *Metabolic Brain Disease*. 2021 [accepted].
283. Hussen BM, Honarmand Tamizkar K, Hidayat J, Taheri M, **Ghafouri-Fard S**. The role of circular RNAs in the development of hepatocellular carcinoma. *Pathology-Research and Practice*. 2021, 223, 153495.
284. **Ghafouri-Fard S**, Hussen BM, Taheri M, Ayatollahi SA. Emerging role of circular RNAs in breast cancer. *Pathology-Research and Practice*. 2021, 223, 153496.
285. Asadi MR, Moslehian MS, Sabaie H, Jalaie A, **Ghafouri-Fard S**, Taheri M, Rezazadeh M. Stress granules and neurodegenerative disorders: A scoping review. *Journal: Frontiers in Aging Neuroscience*. 2021 [accepted].
286. **Ghafouri-Fard S**, Dashti S, Farsi M, Taheri M, Mousavinejad SA. X-inactive-specific transcript: review of its functions in the carcinogenesis. *Frontiers in Cell and Developmental Biology*, section Molecular and Cellular Oncology. 2021 [accepted].
287. **Ghafouri-Fard S**, Agabalazadeh A, Abak A, Shoorei H, Hassanzadeh Taheri MM, Taheri M, Sharifi G. Role of long non-coding RNAs in conferring resistance in tumors of the nervous system. *Frontiers in Oncology*, section Molecular and Cellular Oncology. 2021, 11, 670917.
288. **Ghafouri-Fard S**, Noroozi R, Abak A, Taheri M, Salimi A. Emerging role of lncRNAs in the regulation of Rho GTPase pathway. *Biomedicine and pharmacotherapy*. 2021, 140, 111731.

289. Taheri M, Honarmand Tamizkar K, Omrani S, Arsang-Jang S, **Ghafouri-Fard S**, Omrani MD. MEG3 lncRNA is over-expressed in autism spectrum disorder. *Metabolic Brain Disease*. 2021 [accepted].
290. **Ghafouri-Fard S**, Eghtedarian R, Hussen BM, Motevaseli E, Arsang-Jang S, Taheri M. Expression analysis of VDR-related lncRNAs in autism spectrum disorder. *Journal of Molecular Neuroscience*. 2021, 71(7), pp. 1403–1409.
291. ...**Ghafouri-Fard S**. Discrimination of patients with prostate cancer from healthy persons using a set of single nucleotide polymorphisms. *Urology Journal*. 2021 [accepted].
292. **Ghafouri-Fard S**, Taheri M, Hussen BM, Abak A, Vafae R. Function of circular RNAs in the pathogenesis of colorectal cancer. *Biomedicine and pharmacotherapy*. 2021, 140, 111721
293. **Ghafouri-Fard S**, Eghtedarian R, Taheri M, Brühl A, Sadeghi Bahmani D, Brand S. A Review on the Expression Pattern of Non-coding RNAs in Patients With Schizophrenia: With a Special Focus on Peripheral Blood as a Source of Expression Analysis. *Frontiers in Psychiatry*, section Schizophrenia. 2021, 12:640463.
294. **Ghafouri-Fard S**, Badrlou E, Taheri M, Dürsteler K, Brühl A, Sadeghi Bahmani D, Brand S. A comprehensive review on the role of non-coding RNAs in the pathophysiology of bipolar disorder. *International Journal of Molecular Sciences*. 2021 [accepted].
295. Gholami L, Movafagh A, Badrlou E, Nazer N, Yari M, Sadeghi G, Mirzajani S, Shadnoush M, Sayad A, **Ghafouri-Fard S**. Altered expression of STAT genes in periodontitis. *Human Antibodies*. 2021 [accepted].
296. Abak A, Shoorei H, Taheri M, **Ghafouri-Fard S**. In vivo engineering of chromosome 19 q-arm by employing the CRISPR/AsCpf1 and ddAsCpf1 systems in human malignant gliomas (Hypothesis). *Journal of Molecular Neuroscience*. 2021 [accepted].
297. Gharesouran J, Hosseinzadeh H, **Ghafouri-Fard S**, Taheri M, Rezazadeh M. STRs; Ancient architectures of the genome beyond the sequence. *Journal of Molecular Neuroscience*. 2021 [accepted].
298. **Ghafouri-Fard S**, Hussen BM, Nicknafs F, Nazer N, Sayad A, Taheri M. Expression analysis of Protein inhibitor of activated STAT in inflammatory demyelinating polyradiculoneuropathy. *Frontiers in Immunology*, section Autoimmune and Autoinflammatory Disorders. 2021 [accepted].
299. Taheri M, Younesi Z, Moradi S, ...**Ghafouri-Fard S**, Neishabouri SM. Altered expression of CCAT1 and CCAT2 lncRNAs in autism spectrum disorder. *Gene Reports*. 2021, 23, 101172.
300. Hussen BM, Azimi T, Hidayat HJ, Taheri M, **Ghafouri-Fard S**. NF-KappaB Interacting LncRNA: review of its roles in neoplastic and non-neoplastic conditions. *Biomedicine and Pharmacotherapy*. 2021, 139, 111604.
301. Hussen BM, Azimi T, Hidayat HJ, Taheri M, **Ghafouri-Fard S**. Long noncoding RNA RMRP in the pathogenesis of human disorders. *Frontiers in Cell and Developmental Biology*, section Molecular and Cellular Oncology. 2021 [accepted].

- 302...., **Ghafouri-Fard S**,... DOCK8-related immunodeficiency syndrome (DIDS): report of novel mutations in Iranian patients. *Journal of Molecular Neuroscience*. 2021 [accepted].
- 303.Safa A, Gharebaghi A, Eghtedarian R, Taheri M, **Ghafouri-Fard S**. LncRNA signature in colorectal cancer. *Pathology – Research and Practice*. 2021, 222, 153432.
- 304.**Ghafouri-Fard S**, Gholipour M, Taheri M. microRNA signature in melanoma: biomarkers and therapeutic targets. *Frontiers in Oncology, section Skin Cancer*. 2021 [accepted].
- 305.**Ghafouri-Fard S**, Shaterabadi D, Abak A, Shoorei H, Bahroudi Z, Taheri M. An update on the role of miR-379 in human disorders. *Biomedicine and Pharmacotherapy*. 2021, 139, 111553.
- 306.**Ghafouri-Fard S**, Abak A, Tondro Anamag F, Shoorei H, Fattahi F, Javadinia SA, Basiri A, Taheri M. 5-Fluorouracil: mechanisms of action, introducing cutting-edge strategies, and molecular insights into non-coding RNAs driven modulation of this chemotherapeutic agent. *Frontiers in Oncology, section Cancer Molecular Targets and Therapeutics*. 2021 [accepted].
- 307.**Ghafouri-Fard S**, Aghazadeh Shabestari F, Vaezi S, Abak A, Shoorei H, Karimi A, Taheri M, Basiri A. Emerging impact Quercetin in the treatment of prostate cancer. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
- 308...., **Ghafouri-Fard S**,..., Identification of FDA Approved Drugs Against SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp) and 3-chymotrypsin-like Protease (3CLpro), Drug Repurposing Approach. *Biomedicine and Pharmacotherapy*. 2021, 138, 111544.
- 309.Taheri M, Tondro Anamag F, Shoorei H, Dinger ME, **Ghafouri-Fard S**. The role of miRNAs and lncRNAs in conferring resistance to doxorubicin. *Journal of Drug Targeting*. 2021 [accepted].
- 310.**Ghafouri-Fard S**, Niazi V, Taheri M, Basiri A. Effect of small molecule on ex vivo expansion of cord blood hematopoietic stem cells: a concise review. *Frontiers in Cell and Developmental Biology, section Stem Cell Research*. 2021 [accepted].
- 311.**Ghafouri-Fard S**, Gholipour M, Mahmud Hussien B, Taheri M. The impact of long non-coding RNAs in the pathogenesis of hepatocellular carcinoma. *Frontiers in Oncology*. 2021 [accepted].
- 312.**Ghafouri-Fard S**, Gholipour M, Taheri M. Role of microRNAs in the pathogenesis of coronary artery disease. *Frontiers in Cardiovascular Medicine*. 2021 [accepted].
- 313.Hussein BM, ..., Taheri M, **Ghafouri-Fard S**. MicroRNA: A signature for cancer progression. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
- 314.**Ghafouri-Fard S**, Hesami O, Nazer N, Sayad A, Taheri M. Expression of PIAS genes in migraine patients. *Journal of Molecular Neuroscience*. 2021 [accepted].
- 315.**Ghafouri-Fard S**, Abak A, Fattahi F, Bahroudi Z, Shoorei H, Taheri M. The interaction between miRNAs/lncRNAs and nuclear factor- κ B (NF- κ B) in human disorders. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
- 316.Behtaji S, **Ghafouri-Fard S**, Sayad A, Sattari A, Rederstorff M, Taheri M. Identification of oxytocin-related lncRNAs and assessment of their expression in breast cancer. *Scientific Reports*. 2021, 11(1), 6471.

317. **Ghafouri-Fard S**, Abak A, Mohaqiq M, Shoorei H, Taheri M. Interaction between non-coding RNAs and JNK in human disorders. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
318. **Ghafouri-Fard S**, Glassy MC, Abak A, Hussen BM, Niazi V, Taheri M. The interaction between miRNAs/lncRNAs and Notch pathway in human disorders. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
319. **Ghafouri-Fard S**,..., Shoorei H, Taheri M. Counteracting effects of heavy metals and antioxidants on male fertility. *BioMetals*. 2021 [accepted].
320. Noroozi R, **Ghafouri-Fard S**, Pisarek A, Rudnicka J, Spólnicka M, Branicki W, Taheri M, Pośpiech E. DNA methylation-based age clocks: from age prediction to age reversion. *Ageing Research Reviews*. 2021, 68, 101314.
321. Mahmud Hussen B, Shoorei H, Mohaqiq M, Dinger ME, Hidayat H, Taheri M, **Ghafouri-Fard S**. The impact of non-coding RNAs in the epithelial to mesenchymal transition. *Frontiers Molecular Biosciences*. 2021 [accepted].
322. **Ghafouri-Fard S**, Shoorei H, Bahroudi Z, Abak A, Taheri M. The role of H19 lncRNA in conferring chemoresistance in cancer cells. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
- 323...., **Ghafouri-Fard S**. Emerging role of non-coding RNAs in the pathogenesis of amyotrophic lateral sclerosis. *Metabolic Brain Disease*. 2021 [accepted].
324. Samadian M, Gholipour M, Hajjesmaeili M, Taheri M, **Ghafouri-Fard S**. The eminent role of microRNAs in the pathogenesis of Alzheimer's disease. *Frontiers Aging Neuroscience*. 2021 [accepted].
325. **Ghafouri-Fard S**, Dashti S, Farsi M, M Taheri. BCYRN1: an oncogenic lncRNA in diverse cancers. *Pathology – Research and Practice*. 2021 [accepted].
326. **Ghafouri-Fard S**, Shoorei H, Mohaqiq M, Abbas Raza SH, Taheri M. The role of different compounds on the integrity of blood-testis barrier: a concise review based on in vitro and in vivo studies. *Gene*. 2021 [accepted].
327. **Ghafouri-Fard S**,..., Taheri M. An update on the role of long non-coding RNAs in the pathogenesis of breast cancer. *Pathology – Research and Practice*. 2021 [accepted].
328. **Ghafouri-Fard S**,..., Taheri M. A review on the role of oncogenic lncRNA OIP5-AS1 in human malignancies. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
329. **Ghafouri-Fard S**,... MicroRNA signature in liver cancer. *Pathology - Research and Practice*. 2021 [accepted].
330. Sattari A, **Ghafouri-Fard S**, Omrani MD, Zekri A, Taheri M. Expression of T helper 1-associated lncRNAs in breast cancer. *Experimental and Molecular Pathology*. 2021 [accepted].
331. **Ghafouri-Fard S**, Abak A, Mohaqiq M, Shoorei H, Taheri M. The interplay between non-coding RNAs and insulin-like growth factor (IGF) signaling in the pathogenesis of neoplasia. *Frontiers Cell and Developmental Biology*. 2021 [accepted].

332. **Ghafouri-Fard S**, Shoorei H, Mohaqiq M, Majidpoor J, Mossavi MA, Taheri M. Exploring the role of non-coding RNAs in autophagy. *Autophagy*. 2021 [accepted].
333. **Ghafouri-Fard S**, ... Altered expression of lncRNAs in autism spectrum disorder. *Metabolic Brain Disease*. 2021 [accepted].
334. Mahmud Hussien B, Nicknafs F, Jamal Hidayat H, Sayad A, **Ghafouri-Fard S**, Taheri M. A diagnostic panel for acquired immune-mediated polyneuropathies based on expression of lncRNAs. *Frontiers in Immunology*. 2021 [accepted].
335. **Ghafouri-Fard S**,.. Altered IFN- γ levels after treatment of epileptic patients with omega-3 fatty acids. *Journal of Molecular Neuroscience*. 2021 [accepted].
336. **Ghafouri-Fard S**,.. Assessment of the role of non-coding RNAs in the pathophysiology of Parkinson's disease. *European Journal of Pharmacology*. 2021 [accepted].
337. Maleki P, Mowla SJ, Taheri M, **Ghafouri-Fard S**, Raheb J. The Role of Long intergenic Non-coding RNA for Kinase Activation (LINK-A) as an Oncogene in Non-small Cell Lung Carcinoma. *Scientific Reports*. 2021, 11(1), 4210.
338. Gharesouran J, Hosseinzadeh H, **Ghafouri-Fard S**, Jabbari Moghadam Y, Ahmadian Heris J, Jafari-Rouhi AM, Taheri M, Rezazadeh M. New Insight into Clinical Heterogeneity and Inheritance Diversity of FBLN5-related Cutis Laxa. *Orphanet Journal of Rare Diseases*. 2021, 16(1), 51.
339. **Ghafouri-Fard S**. Expression of apoptosome-related genes in periodontitis. *Gene Reports*. 2021 [accepted].
340. **Ghafouri-Fard S**, Gholipour M, Taheri M. The emerging role of long non-coding RNAs and circular RNAs in coronary artery disease *Journal: Frontiers in Cardiovascular Medicine, section General Cardiovascular Medicine*. Accepted [2021].
341. **Ghafouri-Fard S**, ..., Taheri M. Contribution of extracellular vesicles in normal hematopoiesis and hematological malignancies. *Heliyon*. 2021 [accepted].
342. **Ghafouri-Fard S**, ..., Taheri M. The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process. *Biomedicine and Pharmacotherapy*. 2021 [accepted].
343. Rezaei O, Nateghinia S, Asghari Estiar M, Taheri M, **Ghafouri-Fard S**. Assessment of the role of non-coding RNAs in the pathophysiology of Parkinson's disease. *The European Journal of Pharmacology*. 2021 [accepted].
344. Rezaei O, Honarmand K, Hajiesmaeili M, Taheri M, **Ghafouri-Fard S**. Non-coding RNAs participate in the pathogenesis of neuroblastoma. *Frontiers Oncology*. 2021 [accepted].
345. Taheri M, Shoorei H, Tondro Anamag F, **Ghafouri-Fard S**, Dinger ME. lncRNAs and miRNAs participate in determination of sensitivity of cancer cells to cisplatin. *Experimental and Molecular Pathology*. 2021 [accepted].

346. **Ghafouri-Fard S**, Bahroudi Z, Shoorei H, Abak A, Ahin M, Taheri M. microRNA-140: Roles in Tumorigenesis and Human Diseases. *Biomedicine & Pharmacotherapy*. 2021 [accepted].
347. **Ghafouri-Fard S**, Abak A, Bahroudi Z, Shoorei H, Abbas Raza SH, Taheri M. The interplay between non-coding RNAs and Twist1 signaling contribute to human disorders. *Biomedicine & Pharmacotherapy*. 2021 [accepted].
348. Akbari Dilmaghnaei N, Shoorei H, Sharifi G, Mohaqiq M, Majidpoor J, Dinger ME, Taheri M, **Ghafouri-Fard S**. Non-coding RNAs modulate function of extracellular matrix proteins. *Biomedicine & Pharmacotherapy*. 2021 [accepted].
349. **Ghafouri-Fard S**, Shirvani-Farsani Z, Taheri M. The critical roles of lncRNAs in the development of osteosarcoma. *Biomedicine & Pharmacotherapy*. 2021 [accepted].
350. **Ghafouri-Fard S**..., Taheri M. A comprehensive review on the role of genetic factors in the pathogenesis of migraine. *Journal of Molecular Neuroscience*. 2020 [accepted].
351. **Ghafouri-Fard S**..., Taheri M. An update on the role of miR-124 in the pathogenesis of human disorders. *Biomedicine & Pharmacotherapy*. 2020 [accepted].
352. Ebahimzadeh K, Shoorei H, Mousavinejad SA, Tondro Anamag F, Dinger ME, Taheri M, **Ghafouri-Fard S**. Emerging role of non-coding RNAs in response of cancer cells to radiotherapy. *Pathology - Research and Practice*. 2020 [accepted].
353. Rezaei O, Honarmand K, Sharifi G, Taheri M, **Ghafouri-Fard S**. Emerging role of long non-coding RNAs in the pathobiology of glioblastoma. *Frontiers in Oncology, section Neuro-Oncology and Neurosurgical Oncology*. 2020 [accepted].
354. Lavasani A, Sattari A, Yousefi H, Omrani MD, Nazer N, **Ghafouri-Fard S**, Taheri M. Opposite trends of GAS6 and GAS6-AS expressions in breast cancer tissues. *Experimental and Molecular Pathology*. 2020 [accepted].
355. **Ghafouri-Fard S**, Shoorei H, Abak A, Abbas Raza SH, Pichler M, Taheri M. Role of non-coding RNAs in modulating the response of cancer cells to paclitaxel treatment. *Biomedicine & Pharmacotherapy*. 2020 [accepted].
356. **Ghafouri-Fard S**, Niazi , Taheri M. Role of miRNAs and lncRNAs in hematopoietic stem cell differentiation. *Non-coding RNA Research*. 2020 [accepted].
357. **Ghafouri-Fard S**, Atarbashi-Moghadam S, Taheri M. Genetic factors in the pathogenesis of ameloblastoma, dentigerous cyst and Odontogenic keratocyst. *GENE*. 2020 [accepted].
358. **Ghafouri-Fard S**. Taheri M. The expression profile and role of non-coding RNAs in obesity. *The European Journal of Pharmacology*. 2020 [accepted].
359. **Ghafouri-Fard S**, Dashti S, Farsi M, Taheri M. Deleted in lymphocytic leukemia 2 (DLEU2): an lncRNA with dissimilar roles in different cancers. *Biomedicine & Pharmacotherapy*. 2020 [accepted].
360. **Ghafouri-Fard S**, Dashti S, Farsi M, Taheri M. HOX transcript antisense RNA: an oncogenic lncRNA in diverse malignancies. *Experimental and Molecular Pathology*. 2020 [accepted].
361. **Ghafouri-Fard S**. Dashti S, Taheri M. Myocardial infarction associated transcript (MIAT): review of its impact in the tumorigenesis . *Biomedicine & Pharmacotherapy*. 2020 [accepted].

362. **Ghafouri-Fard S**...A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis. *Metabolic Brain Disease*. 2020 [accepted].
363. **Ghafouri-Fard S**,..., Taheri M. Assessment of association between HLA alleles and acquired aplastic anemia in Iranian population. *Ecological Genetics and Genomics*. 2020 [accepted].
364. **Ghafouri-Fard S**,..., Taheri M. Role of miRNAs in conveying message of stem cells via extracellular vesicles. *Experimental and Molecular Pathology*. 2020 [accepted].
365. **Ghafouri-Fard S**, Abak A, Shoorei H, Mohaqiq M, Majidpoor J, Sayad A, Taheri M. Regulatory role of microRNAs on PTEN signaling. *Biomedicine and Pharmacotherapy*. 2020 [accepted].
366. **Ghafouri-Fard S**...MicroRNA profile in the squamous cell carcinoma: prognostic and diagnostic roles. *Heliyon*. 2020 [accepted].
367. **Ghafouri-Fard S**, Mazdeh M, Nicknafs F, Nazer N, Sayad A, Taheri M. Expression analysis of BDNF, BACE1 and their antisense transcripts in inflammatory demyelinating polyradiculoneuropathy. *Multiple Sclerosis and Related Disorders*. 2020 [accepted].
368. Liaghati P, Momeni P, Esfandi F, Kholghi Oskooei V, Sattari A, **Ghafouri-Fard S**, Taheri M. Expression analysis of CD24 and CD44 transcripts in Iranian breast cancer patients. *Breast Disease*. 2020 [accepted].
369. Patoughi M, **Ghafouri-Fard S**, Arsang-Jang S, Taheri M. Expression analysis of PINK1 and PINK1-AS in Multiple Sclerosis patients versus healthy subjects. *Nucleosides, Nucleotides & Nucleic Acids*. 2020 [accepted].
370. **Ghafouri-Fard S**, Shoorei H, Tondro Anamag F, Taheri M. The role of non-coding RNAs in controlling cell cycle related proteins in cancer cells. *Frontiers in Oncology*. 2020 [accepted].
371. **Ghafouri-Fard S**... Non-coding RNAs and type 2 diabetes mellitus. *Archives of Physiology and Biochemistry*. 2020 [accepted].
372. Taheri M, Nicknafs F, Hesami O, Javadi A, Arsang-Jang S, Sayad A, **Ghafouri-Fard S**. Differential expression of cytokine-coding genes among migraine patients with and without aura and normal subjects. *Journal of Molecular Neuroscience*. 2020 [accepted].
373. Mazdeh M, Taheri M, **Ghafouri-Fard S**. Investigation of sexual satisfaction in women with epilepsy and their clinical correlates. *Journal of Molecular Neuroscience*. 2020 [accepted].
374. **Ghafouri-Fard S**, Shirvani Z, Branicki W, Taheri M. MicroRNA signature in renal cell carcinoma. *Frontiers in Oncology*. 2020 [accepted].
375. Sadri Kandjani F, **Ghafouri-Fard S**, Gharesouran J, Mokhtari Z, Ghahremanzadeh K, Hiradfar A, Kholghi Oskooei V, Taheri M, Rezazadeh M. A single nucleotide polymorphism in the interferon regulatory factor 8 gene is associated with risk of AML in Iranian population. *Ecological Genetics and Genomics*. 2020 [accepted].
376. Dashti S, Taheri M, **Ghafouri-Fard S**. An in-silico method leads to recognition of hub genes and crucial pathways in survival of patients with breast cancer. *Scientific Reports*. 2020 [accepted].

377. Safa A, Gholipour M, Dinger ME, Taheri M, **Ghafouri-Fard S**. The critical roles of lncRNAs in the pathogenesis of melanoma. *Experimental and Molecular Pathology*. 2020 [accepted].
- 378....**Ghafouri-Fard S**. Expression of NF- κ B associated lncRNAs in schizophrenia. *Scientific Reports*. 2020 [accepted].
- 379....**Ghafouri-Fard S**...The communication between stromal and hematopoietic stem cells by exosomes in normal and malignant bone marrow niche. *Biomedicine and Pharmacotherapy*. 2020 [accepted].
- 380....**Ghafouri-Fard S**. MicroRNAs as regulators of ERK/MAPK pathway: a comprehensive review. *Biomedicine and Pharmacotherapy*. 2020 [accepted].
381. Rezaei O, Honarmand K, Nateghinia S, Taheri M, **Ghafouri-Fard S**. miRNA signature in glioblastoma: potential biomarkers and therapeutic targets. *Experimental and Molecular Pathology*. 2020 [accepted].
382. Safa A, Azimi T, Sayad A, Taheri M, **Ghafouri-Fard S**. A review on the role of genetic factors in Guillain–Barré syndrome. *Journal of Molecular Neuroscience*. 2020 [accepted].
383. Sadeghpour S, **Ghafouri-Fard S**, Mazdeh M, Nicknafs F, Nazer N, Sayad A, Taheri M. Over-expression of immune-related lncRNAs in inflammatory demyelinating polyradiculoneuropathies. *Journal of Molecular Neuroscience*. 2020 [accepted].
384. Mohebi M, Sattari A, **Ghafouri-Fard S**, Modarressi MH, Samsami M, Kholghi-Oskooei V, Taheri M. Expression profiling revealed up-regulation of three lncRNAs in breast cancer samples. *Experimental and Molecular Pathology*. 2020 [accepted].
- 385...., **Ghafouri-Fard S**...Clinical and genetic features of PEHO and PEHO-Like syndromes: A scoping review. *Biomedicine and Pharmacotherapy*. 2020 [accepted].
386. Taheri M, Eghtedarian R, Dinger ME, **Ghafouri-Fard S**. Dysregulation of non-coding RNAs in autoimmune thyroid disease. *Experimental and Molecular Pathology*. 2020 [accepted].
- 387...., **Ghafouri-Fard S**. Clinical and demographic characteristics of patients with COVID-19 infection: statistics from a single hospital in Iran. *Human Antibodies*. 2020 [accepted].
388. Taheri M, Shirvani Farsani Z, **Ghafouri-Fard S**, Omrani MD. Expression profile of microRNAs in bladder cancer and their application as biomarkers. *Biomedicine and Pharmacotherapy*. 2020 [accepted].
389. Safa A, Omrani MD, Nicknafs F, Komaki A, Taheri M, **Ghafouri-Fard S**. A single nucleotide polymorphism within Molybdenum Cofactor Sulfurase gene is associated with neuropsychiatric conditions. *Frontiers in Molecular Biosciences*. 2020 [accepted].
390. **Ghafouri-Fard S**, Shoorei H, Taheri M. The role of long non-coding RNAs in cancer metabolism: a concise review. *Frontiers in Oncology*. 2020 [accepted].
391. Noroozi R, Dinger ME, Fatehi R, Taheri M, **Ghafouri-Fard S**. Identification of miRNA-mRNA network in autism spectrum disorder using a bioinformatics method. *Molecular Neuroscience*. 2020 [accepted].

392. Behnaz M, Jazaeri M, Aghandeh P, Taheri M, **Ghafouri-Fard S**. Genetic factors in determination of risk of external apical root resorption: a concise review. *Gene Reports*. 2020 [accepted].
393. Liaghati P, Momeni P, Kholghi Oskooei V, **Ghafouri-Fard S**, Taheri M. Expression levels of ABCG2 and CD61 genes in breast cancer tissues of Iranian population. *Breast Disease*. 2020 [accepted].
394. **Ghafouri-Fard S**, Shoorei H, Mohaqiq M, Taheri M. Non-coding RNAs regulate angiogenic processes. *Vascular Pharmacology*. 2020 [accepted].
395. Sayad A, Gholami L, Mirzajani S, Omrani MD, **Ghafouri-Fard S**, Taheri M. Genetic susceptibility for periodontitis with special focus on immune-related genes: a concise review. *Gene Reports*. 2020 [accepted].
396. **Ghafouri-Fard S**, Shoorei H, Taheri M, Sanak M. Emerging role of non-coding RNAs in allergic disorders. *Biomedicine and pharmacotherapy*. 2020 [accepted].
397. Taheri M, Eghtedarian R, Dinger M, **Ghafouri-Fard S**. Dysregulation of non-coding RNAs in Rheumatoid arthritis. *Biomedicine and pharmacotherapy*. 2020 [accepted].
398. Taheri M, Shoorei H, Dinger M, **Ghafouri-Fard S**, Perspectives on the role of non-coding RNAs in the regulation of expression and function of the estrogen receptor. *Cancer*. 2020 [accepted].
399. Mirzajani S, **Ghafouri-Fard S**, Mehvari Habibabadi J, Glassy MC, Sayad A, Taheri M. Altered ANRIL methylation in epileptic patients. *Journal of Molecular Neuroscience*. 2020 [accepted].
400. Afrough H, **Ghafouri-Fard S**, Yousefi H, Kholghi Oskooei V, Samsami M, Taheri M. DICER-AS1 lncRNA: a putative culprit in the pathogenesis of gastric cancer. *Experimental and Molecular Pathology*. 2020 [accepted].
401. Taheri M, Eghtedarian R, Dinger ME, **Ghafouri-Fard S**. Emerging roles of non-coding RNAs in the pathogenesis of type 1 diabetes mellitus. *Biomedicine and pharmacotherapy*. 2020 [accepted].
402. **Ghafouri-Fard S**, Eghtedarian R, Taheri M. The crucial role of non-coding RNAs in the pathophysiology of inflammatory bowel disease. *Biomedicine and pharmacotherapy*. 2020 [accepted].
403. **Ghafouri-Fard S**, Vafae R, Shoorei H, Taheri M. microRNAs in gastric cancer: biomarkers and therapeutic targets. *Gene*. 2020 [accepted].
404. Safa A, Noroozi R, Taheri M, **Ghafouri-Fard S**. Association analysis of ANRIL polymorphisms and haplotypes with autism spectrum disorders. *Journal of Molecular Neuroscience*. 2020 [accepted].
405. **Ghafouri-Fard S**, Dashti S, Taheri M, Omrani MD. TINCR: an lncRNA with dual functions in the carcinogenesis process. *Non-coding RNA Research*. 2020 [accepted].
406. **Ghafouri-Fard S**, Shoorei, Taheri M. Role of non-coding RNAs in the pathogenesis of endometriosis. *Frontiers in Oncology, section Molecular and Cellular Oncology*. 2020 [accepted].

407. **Ghafouri-Fard S**, Eghtedarian R, Taheri M, Rakhshan A. The eminent roles of ncRNAs in the pathogenesis of psoriasis. *Non-coding RNA Research*. 2020 [accepted].
408. Safa A, Taheri M, Fallah H, Salmani T, Arsang-Jang S, **Ghafouri-Fard S**, Omrani MD. Down-regulation of cancer-associated lncRNAs in peripheral blood of multiple sclerosis patients. *Journal of Molecular Neuroscience*. 2020 [accepted].
409. **Ghafouri-Fard S**, Shirvani Farsani Z, Taheri M. The role of microRNAs in the pathogenesis of thyroid cancer. *Non-coding RNA Research*. 2020 [accepted].
410. **Ghafouri-Fard S**, Shoorei H, Taheri M. Non-coding RNAs participate in the ischemia-reperfusion injury. *Biomedicine & Pharmacotherapy*. 2020 [accepted].
411. Yaghoobi H, Azizi H, Kholghi Oskooei V, Taheri M, **Ghafouri-Fard S**. PTEN-induced putative kinase 1 (PINK1) down-regulation in breast cancer samples in association with mitotic rate. *MetaGene*. 2020 [accepted].
412. Rezaei S, **Ghafouri-Fard S**, Komaki A, Mazdeh M, Taheri M, Eftekharian MM. Increased levels of IL-34 in acquired immune-mediated neuropathies. *Journal of Molecular Neuroscience*. 2020 [accepted].
413. Taheri M, Eghtedarian R, Dinger M, **Ghafouri-Fard S**. Exploring the role of non-coding RNAs in the pathophysiology of systemic lupus erythematosus. *Biomolecules*. 2020 [accepted].
414. Sayad A, Mirzajani S, Gholami L, Razzaghi P, **Ghafouri-Fard S**, Taheri M. Emerging role of long non-coding RNAs in the pathogenesis of periodontitis. *Biomedicine & Pharmacotherapy*. 2020 [accepted].
415. Gharesouran J, Jalaie A, Hosseinzadeh A, **Ghafouri-Fard S**, Mokhtari Z, Ghahremanzadeh K, Rezazadeh N, Shiva S, Sadeghvand S, Taheri M, Rezazadeh M. GAA gene mutation detection following clinical evaluation and enzyme activity analysis in Azeri Turkish patients with Pompe disease. *Metabolic Brain Disease*. 2020 [accepted].
416. Safa A, Arsang-Jang S, Taheri M, Omrani MD, **Ghafouri-Fard S**. Dysregulation of NF- κ B-associated lncRNAs in multiple sclerosis patients. *Journal of Molecular Neuroscience*. 2020 [accepted].
417. Salehnezhad T, Hajati F, Mir Hassani Z, Esfandi F, Kholghi-Oskooei V, Taheri M, **Ghafouri-Fard S**, Samsami M. Assessment of expression of vitamin D receptor-associated lncRNAs in gastric cancer. *Meta Gene*. 2020 [accepted].
418. Kahaei MS, **Ghafouri-Fard S**, Namvar A, Omrani MD, Sayad A, Taheri M. Association study of a single nucleotide polymorphism in brain cytoplasmic 200 long-noncoding RNA and psychiatric disorders. *Metabolic Brain Disease*. 2020 [accepted].
419. Noroozi R, Branicki W, Pyrc K, Łabaj P, Pošpiech E, Taheri M, **Ghafouri-Fard S**. Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions. *Cytokine*. 2020 [accepted].

420. **Ghafouri-Fard S**, Noroozi R, Vafae R, Branicki W, Pošpiech E, Pyrc K, Labaj P, Omrani MD, Taheri M, Sanak M. Effects of host genetic variations on response to, susceptibility and severity of respiratory infections. *Biomedicine & Pharmacotherapy*. 2020 [accepted].
421. **Ghafouri-Fard S**, Shoorei H, Dashti S, Branicki W, Taheri M. Expression profile of lncRNAs and miRNAs in esophageal cancer: implications in diagnosis, prognosis and therapeutic response. *Journal of cellular Physiology*. 2020 [accepted].
422. Gheliji T, Kholghi Oskooei V, Ashrafi Hafez A, Taheri M, **Ghafouri-Fard S**. Evaluation of expression of vitamin D receptor related lncRNAs in lung cancer. *Non-coding RNA Research*. 2020 [accepted].
423. Sayad A, **Ghafouri-Fard S**, Sadeghpour S, Mirzajani S, Taheri M, Arsang-Jang S, Ahmadzadeh Raji M, Houshmand B, Amid R, Gholami L, Shams B. Dysregulation of GAS5 and OIP5-AS1 lncRNAs in periodontitis. *Gene Reports*. 2020 [accepted].
424. Safa A, Omrani MD, Nicknafs F, Kholghi Oskooei V, Taheri M, **Ghafouri-Fard S**. Assessment of association between NINJ2 polymorphisms and suicide attempt in Iranian population. *Journal of Molecular Neuroscience*. 2020 [accepted].
425. Dashti S, Taherian-Esfahani Z, Kholghi-Oskooei V, Noroozi R, Arsang-Jang S, **Ghafouri-Fard S**, Taheri M. In silico identification of MAPK14-related lncRNAs and assessment of their expression in breast cancer samples. *Scientific Reports*. 2020 [accepted].
426. Saffarzadeh N, **Ghafouri-Fard S**, Rezaei Z, Aghazadeh K, Yazdani F, Mohebi M, Ahmadi M, Shakoori A, Tavakkoly-Bazzaz J. Expression analysis of GRHL3 and PHLDA3 in head and neck squamous cell carcinoma. *Cancer Management and Research*. 2020 [accepted].
427. **Ghafouri-Fard S**, Noroozi R, Omrani MD, Branicki W, Pošpiech E, Sayad A, Pyrc K, Labaj PP, Taheri M, Sanak M. Angiotensin converting enzyme: a review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection. *Vascular Pharmacology*. 2020 [accepted].
428. **Ghafouri-Fard S**, Shoorei H, Taheri M. Non-coding RNAs are involved in the response to oxidative stress. *Biomedicine & Pharmacotherapy*. 2020 [accepted].
429. Sayad A, **Ghafouri-Fard S**, Shams B, Arsang-Jang S, Gholami L, Taheri M. Sex-specific up-regulation of p50-associated COX-2 extragenic RNA (PACER) lncRNA in periodontitis. *Heliyon*. 2020 [accepted].
430. **Ghafouri-Fard S**, Dashti S, Taheri M. The role of long non-coding RNA CASC2 in the carcinogenesis process. *Biomedicine & Pharmacotherapy*. 2020 [accepted].
431. **Ghafouri-Fard S**, Taheri M. Highly up-regulated in liver cancer (HULC): an update on its role in carcinogenesis. *Journal of Cellular Physiology*. 2020 [accepted].
432. Sayad A, **Ghafouri-Fard S**, Shams B, Arsang-Jang S, Gholami L, Taheri M. Blood and tissue levels of lncRNAs in periodontitis. *Journal of Cellular Physiology*. 2020 [accepted].

433. **Ghafouri-Fard S**, Taheri. A comprehensive review of non-coding RNAs functions in multiple sclerosis. *European Journal of Pharmacology*. 2020 [accepted].
434. Shams R, Saberi S, Zali M, Sadeghi A, **Ghafouri-Fard S**, Asadzadeh Aghdaei H. Identification of potential microRNA panels for pancreatic cancer diagnosis using microarray datasets and bioinformatics methods. *Scientific Reports*. 2020 [accepted].
435. Vakili K, Fathi M, Yaghoobpoor S, Deravi N, **Ghafouri-Fard S**. Recurrent IVF failure: review of genetic factors. *Gene Reports*. 2020 [accepted].
436. **Ghafouri-Fard S**, Dashti S, Taheri M. The HOTTIP (HOXA transcript at the distal tip) lncRNA: review of oncogenic roles in human. *Biomedicine & Pharmacotherapy*. 2020 [accepted].
437. **Ghafouri-Fard S**, Shoorei H, Taheri M. The role of microRNAs in ectopic pregnancy: a concise review. *Non-coding RNA Research*. 2020 [accepted].
438. Gholami L, **Ghafouri-Fard S**, Mirzajani S, Arsang-Jang S, Taheri M, Dehbani Z, Dehghani S, Houshmand B, Amid R, Sayad A, Shams B. The lncRNA ANRIL is down-regulated in peripheral blood of patients with periodontitis. *Non-coding RNA Research*. 2020 [accepted].
439. Mohebi M, **Ghafouri-Fard S**, Modarressi MH, Dashti S, Zekri A, Kholghi-Oskooei V, Taheri M. Expression analysis of vimentin and the related lncRNA network in breast cancer. *Experimental and Molecular Pathology*. 2020 [accepted].
440. Javadlar M, Dastar S, Gharesouran J, **Ghafouri-Fard S**, Hosseinzadeh H, Moradi M, Abdi Mazraeh S, Nasiri Ganjineh Ketab F, Rezamand A, Hiraifar A, Taheri M, Rezazadeh M. RUNX1 variant as a genetic predisposition factor for acute myeloid leukemia. *Experimental and Molecular Pathology*. 2020 [accepted].
441. Behnaz M, Mohammad-Rahimi H, Javaheri F, Omrani MD, Noroozi R, Taheri M, **Ghafouri-Fard S**. The rs1143634 of IL-1 β gene is associated with external apical root resorption in Iranian population. *Meta Gene*. 2020 [accepted].
442. Sayad A, Akbari MT, Ostadali Dehaghi M, Hamidieh AA, Arsang-Jang S, Hajifathali A, **Ghafouri-Fard S**, Taheri M. Comprehensive assessment of association between HLA polymorphisms and acute leukemia in Iranian population. *Gene Reports*. 2020 [accepted].
443. **Ghafouri-Fard S**, Dashti S, Taheri M. PCAT1: an oncogenic lncRNA in diverse cancers and a putative therapeutic target. *Experimental and Molecular Pathology*. 2020 [accepted].
444. Mazdeh M, Kordestani H, Komaki A, Eftekharian MM, Arsang-Jang S, Branicki W, Taheri M, **Ghafouri-Fard S**. Assessment of expression profile of microRNAs in multiple sclerosis patients treated with fingolimod. *Journal of Molecular Neuroscience*. 2020 [accepted].
445. **Ghafouri-Fard S**, Taherian-Esfahani Z, Dashti S, Kholghi Oskooei V, Taheri M. Gene expression of indoleamine and tryptophan dioxygenases and three long non-coding RNAs in breast cancer. *Experimental and Molecular Pathology*. 2020 [accepted].

446. Dashti S, Taherian-Esfahani Z, Kholghi-Oskooei V, **Ghafouri-Fard S**, Taheri M. Expression analysis of growth arrest specific 8 and its anti-sense in breast cancer tissues. *Experimental and Molecular Pathology*. 2020 [accepted].
447. Sayad A, Ostadali Dehaghi M, Taheri M, Fallah H, Arsang-Jang S, Shadnoush M, **Ghafouri-Fard S**, Hamidieh AA. Identification of HLA-A/B/DRB1 alleles in Iranian patients with Fanconi anemia. *Human Antibodies*. 2020 [accepted].
448. Taherian-Esfahani Z, **Ghafouri-Fard S**. A bioinformatics approach for identification lncRNA-miRNA-protein interactions for SNHG1 and SNHG5. *Gene Reports*. 2020 [accepted].
449. Sayad A, Taheri M, Sadeghpour S, Omrani MD, Shams B, Mirzajani S, Arsang-Jang S, Houshmand B, Amid R, Gholami L, **Ghafouri-Fard S**. Exploring the role of long non-coding RNAs in periodontitis. *Meta Gene*. 2020 [accepted].
450. **Ghafouri-Fard S**, Shoorei H, Branicki W, Taheri M. Non-coding RNA profile in lung cancer. *Experimental and Molecular Pathology*. 2020 [accepted].
451. Younesi S, Taheri Amin MM, Saadati P, Yazdani B, Jamali S, Modarresi MH, Savad S, Amidi S, **Ghafouri-Fard S**, Razmpoosh E, Yazarlou F. Fine-tuning of routine combined first-trimester screening; the ratio of serum-free-beta-human chorionic gonadotropin (β -hCG) to pregnancy-associated plasma protein-A (PAPP-A) could improve performance of Down syndrome screening program, a retrospective cohort study in Iran. *Human Antibodies*. 2020 [accepted].
452. Mazdeh M, Khamseh M, Taheri M, **Ghafouri-Fard S**, Taheri M. Effect of rituximab on expanded disability status scale and relapse rate in multiple sclerosis patients. *Journal of Molecular Neuroscience*. 2020 [accepted].
453. **Ghafouri-Fard S**, Esmaceli M, Shoorei H, Taheri M. A comprehensive review of the role of long non-coding RNAs in organs with an endocrine function. *Biomedicine & Pharmacotherapy*. 2020 [accepted].
454. Mazdeh M, Khazaie M, Omrani MD, Noroozi R, Komaki A, Karimi M, Taheri M, **Ghafouri-Fard S**. Association between *methylene tetrahydrofolate reductase* polymorphisms and risk of ischemic stroke. *International Journal of Neuroscience*. 2020 [accepted].
455. Mazdeh M, Mahmudian R, Vafaei SY, Taheri M, **Ghafouri-Fard S**. Effect of propranolol with and without rosuvastatin on migraine attacks: a triple blind randomized clinical trial. *Future Neurology*. 2020 [accepted].
456. **Ghafouri-Fard S**, Taheri M, Omrani MD, Doaee A, Mohammad-Rahimi H. Application of artificial neural network for prediction of risk of multiple sclerosis based on single nucleotide polymorphisms genotypes. *Journal of Molecular Neuroscience*. 2020 [accepted].
457. Rakhshan A, Zarrinpour N, Moradi A, Ahadi A, Omrani MD, **Ghafouri-Fard S**, Taheri M. A single nucleotide polymorphism within HOX Transcript Antisense RNA (HOTAIR) is associated with risk of psoriasis. *International Journal of Immunogenetics*. 2020 [accepted].

458. Sayad A, Shams J, Raouf Sarvar S, Omrani MD, Taheri M, **Ghafouri-Fard S**. Assessment of association between the rs2270637 polymorphism of VMAT1 gene and risk of bipolar and major depressive disorders. *Meta Gene*. 2020 [accepted].
459. Taheri M, Sadeghpour S, Norouzi R, **Ghafouri-Fard S**, Ormani MD. The rs4759314 SNP within HOTAIR lncRNA is associated with risk of multiple sclerosis. *Multiple Sclerosis and Related Disorders*. 2020 [accepted].
460. Mazdeh M, Heidari M, Taheri M, **Ghafouri-Fard S**. Anticonvulsant drugs effects on sex hormone levels and sexual function in men with epilepsy. *Future Neurology*. 2020 [accepted].
461. Astaneh M, **Ghafouri-Fard S**, Fazeli Z, Taherian-Esfahani Z, Dashti S, Motevaseli E. Assessment of anti-cancer effects of koenimbine on colon cancer cells. *Human Antibodies*. 2020 [accepted].
462. Nasiri Ganjineh Ketab F, Gharesouran J, **Ghafouri-Fard S**, Dastar S, Abdi Mazraeh S, Hosseinzadeh H, Moradi M, Javadlar M, Hiraifar A, Rezamand A, Rezazadeh M. Dual biomarkers long non-coding RNA GAS5 and its target, NR3C1, contribute to Acute Myeloid Leukemia. *Experimental and Molecular Pathology*. 2020 [accepted].
463. Pour Mohammad Ali Z, Taheri M, Sangseifid S, Arsang-Jang S, Mazdeh M, Zamani A, **Ghafouri-Fard S**, Eftekharian MM. Evaluation of expression of STAT genes in immune-mediated polyneuropathies. *Journal of Molecular Neuroscience*. 2020 [accepted].
464. **Ghafouri-Fard S**, Esmaili M, Taheri M. Expression of non-coding RNAs in hematological malignancies. *EUROPEAN JOURNAL OF PHARMACOLOGY*. 2020 [accepted].
465. Sayad A, Akbari, Hesami O, **Ghafouri-Fard S**, Taheri M, Identification of a mutation in SPG11 in an Iranian patient with spastic paraplegia and ears of the lynx sign. *Journal of Molecular Neuroscience*. 2020 [accepted].
466. Sayad A, Badrlou E, **Ghafouri-Fard S**, Taheri M. Association analysis between the rs1899663 polymorphism of HOTAIR and risk of psychiatric conditions in an Iranian population. *Journal of Molecular Neuroscience*. 2020 [accepted].
467. Esfandi F, Salehnezhad T, Taheri M, Afsharpad M, Ashrafi Hafez A, Kholghi V, **Ghafouri-Fard S**. Expression assessment of a panel of long non-coding RNAs in gastric malignancy. *Experimental and Molecular Pathology*. 2020 [accepted].
468. Mohseni-Salehi FS, Zare-Mirakabad F, Sadeghi M, **Ghafouri-Fard S**. A Stochastic Model of DNA Double-Strand Breaks Repair Throughout the Cell Cycle. *Bulletin of Mathematical Biology*. 2020, 82:11.
469. Motevasselian M, Saleh Gargari S, Younesi S, Pooransari P, Saadati P, Mirzamoradi M, Savad S, Taheri Amin MM, Modarresi MH, Afrakhteh M, **Ghafouri-Fard S**. Non-invasive prenatal testing as screening test for common trisomies in twin pregnancy. *Molecular Cytogenetics*. 2020 [accepted].
470. **Ghafouri-Fard S**, Shoorei H, Taheri M. miRNA profile in ovarian cancer. *Experimental and Molecular Pathology*. 2020 [accepted].
471. **Ghafouri-Fard S**, Taheri M. Long non-coding RNA signature in gastric cancer. *Experimental and Molecular Pathology*. 2019 [accepted].

472. Sobhani M, Tabatabaiefar MA, **Ghafouri-Fard S**, Rajab A, Hojat A, Kajbafzadeh AM, Noori-Daloi MR. Clinical and genetic analysis of two wolfram syndrome families with high occurrence of wolfram syndrome and Diabetes type II: a case report. *BMC Medical Genetics*. 2019 [accepted].
473. Mirzajani S, **Ghafouri-Fard S**, Mehvari Habibabadi J, Arsang-Jang S, Omrani MD, Hashemi Fesharaki SS, Sayad A, Taheri M. Expression analysis of lncRNAs in refractory and non-refractory epileptic patients. *Journal of Molecular Neuroscience*. 2019 [accepted].
474. Mazdeh M, Eftekharian MM, Komaki A, Taheri M, **Ghafouri-Fard S**. Expression analysis of NNT and NNT-AS1 in epileptic patients. *Meta Gene*. 2019 [accepted].
475. Ebadi N, **Ghafouri-Fard S**, Taheri M, Arsang-Jang S, Omrani MD. Expression analysis of inflammatory response-associated genes in coronary artery disease. *Archives Of Physiology And Biochemistry*. 2019 [accepted].
476. Dashti S, **Ghafouri-Fard S**, Esfandi F, Kholghi Oskooei V, Arsang-Jang S, Taheri M. Expression analysis of NF- κ B interacting long noncoding RNAs in breast cancer. *Experimental and Molecular Pathology*. 2019 [accepted].
477. Ebadi N, **Ghafouri-Fard S**, Taheri M, Arsang-Jang S, Alipour Parsa S, Omrani MD. Dysregulation of autophagy-related lncRNAs in peripheral blood of coronary artery disease patients. *European Journal of Pharmacology*. 2019 [accepted].
478. Keshavarzi A, Eftekharian MM, Komaki A, Omrani MD, Kholghi Oskooei V, Taheri M, **Ghafouri-Fard S**. Sexual dimorphism in up-regulation of Suppressors of cytokine signaling genes in patients with bipolar disorder. *BMC Psychiatric*. 2019 [accepted].
479. **Ghafouri-Fard S**, Esmaili M, Taheri. H19 lncRNA: Roles in tumorigenesis. *Biomedicine & Pharmacotherapy*. 2019 [accepted].
480. **Ghafouri-Fard S**, Mohammad-Rahimi H, Jazaeri M, Taheri M. Expression and Function of long non-coding RNAs in head and neck squamous cell carcinoma. *Experimental and Molecular Pathology*. 2019 [accepted].
481. Kahaei MS, **Ghafouri-Fard S**, Namvar A, Omrani MD, Sayad A, Taheri M. Associations between an intronic variant in IL-8 gene and risk of psychiatric disorders. *Ecological Genetics and Genomics*. 2019 [accepted].
482. Sayad A, **Ghafouri-Fard S**, Omrani MD, Taheri M. Associations between two single nucleotide polymorphisms in *NINJ2* gene and risk of psychiatric disorders. *Journal of Molecular Neuroscience*. 2019 [accepted].
483. Azimi G, Ranjbaran F, Arsang-Jang S, **Ghafouri-Fard S**, Mazdeh M, Sayad A, Taheri M. Up-regulation of VEGF-A and correlation between VEGF-A and FLT-1 expressions in Iranian multiple sclerosis patients. *Neurological Sciences*. 2019 [accepted].

484. Safari MR, Dowlati Beirami A, Khazaie M, Komaki A, Noroozi R, **Ghafouri-Fard S**, Taheri M. *GRM7* polymorphisms are not associated with ischemic stroke in Iranian population. *Nucleosides, Nucleotides & Nucleic Acids*. 2019 [accepted].
485. Taheri M, Noroozi R, Aghaei K, Omrani MD, **Ghafouri-Fard S**. The rs594445 in *MOCOS* gene is associated with risk of autism spectrum disorder. *Metabolic Brain Disease*. 2019 [accepted].
486. Niazi Z, Garazhian E, Esfandi F, Mir Hassani Z, Taheri M, **Ghafouri-Fard S**. Expression analysis of the long non-coding RNA LINC01433 in lung cancer. *Klin Onkol*. 2019. 32 (6): 1-3.
487. Abdi Mazraeh S, Gharesouran J, Taheri M, **Ghafouri-Fard S**, Nasiri Ganjineh Ketab F, Hosseinzadeh H, Moradi M, Javadlar M, Hiraifar A, Rezamand A, Rezazadehhh M. Association between *WT1* and *MEG3* polymorphisms and risk of acute myeloid leukemia. *Meta Gene*. 2019 [accepted].
488. Rakhshan A, Zarrinpour N, Moradi A, Ahadi M, Omrani MD, **Ghafouri-Fard S**, Taheri M. Genetic variants within *ANRIL* (antisense non coding RNA in the *INK4* locus) are associated with risk of psoriasis. *International Immunopharmacology*. 2019 [accepted].
489. Moradi M, Gharesouran J, **Ghafouri-Fard S**, Noroozi R, Talebian S, Taheri M, Rezazadeh M. Role of *NR3C1* and *GAS5* genes polymorphisms in Multiple Sclerosis. *The International Journal of neuroscience*. 2019 [accepted].
490. **Ghafouri-Fard S**, Mohammad-Rahimi H, Taheri M. The role of lncRNAs in the pathogenesis of thyroid cancer. *Experimental and Molecular Pathology*. 2019 [accepted].
491. Namvar A, Kahaei MS, Fallah H, Nicknafs F, Azari I, **Ghafouri-Fard S**, Taheri M. *ANRIL* variants are associated with risk of neuropsychiatric conditions. *Journal of Molecular Neuroscience*. 2019 [accepted].
492. Nafar M, Kalantari S, Ghaderian SMH, Omrani MD, Fallah H, Arsang-Jang S, Samavat S, Dalili N, Taheri M, **Ghafouri-Fard S**. Expression levels of lncRNAs in the patients with the renal transplant rejection. *Urology Journal*. 2019 [accepted].
493. **Ghafouri-Fard S**, Ashrafi Hafez A, Taheri M. Metastasis Associated Lung Adenocarcinoma Transcript 1: an update on expression pattern and functions in carcinogenesis. *Experimental and Molecular Pathology*. 2019 [accepted].
494. Saleh Gargari S, **Ghafouri-Fard S**, Zandieh Z, Ansaripour S, Pouresmaeili F, Vatannejad A. The rs16944 SNP in *IL-1B* and risk of polycystic ovarian syndrome. *Gene Reports*. 2019 [accepted].
495. **Ghafouri-Fard S**, Namvar A, Arsang-Jang S, Komaki A, Taheri M. Expression analysis of *BDNF*, *BACE1* and their natural occurring antisenses in autistic patients. *Journal of Molecular Neuroscience*. 2019 [accepted].
496. Fallah H, Sayad A, Ranjbaran F, Talebian F, **Ghafouri-Fard S**, Taheri M. *IFNG/IFNG-AS1* Expression Level Balance: Implications for Autism Spectrum Disorder. *Metabolic Brain Disease*. 2019 [accepted].

497. Mirzaajani S, **Ghafouri-Fard S**,... Peripheral expression of Rubicon Like Autophagy Enhancer is reduced in epileptic patients. *Gene Reports*. 2019 [accepted].
498. Nafar M, Kalantari S, Samavat S, Abbasi T, Arsang-Jang S, Taheri M, **Ghafouri-Fard S**. Down-regulation of protein inhibitor of activated STAT (PIAS) 1 is possibly involved in the process of allograft rejection. *Transplantation Proceedings*. 2019 [accepted].
499. Hashemian F, **Ghafouri-Fard S**, Arsang-Jang S, Mirzajani S, Fallah H, Mehvari Habibabadi J, Sayad A, Taheri M. Epilepsy is associated with dysregulation of long non-coding RNAs in the peripheral blood. *Frontiers in Molecular Bioscience*. 2019 [accepted].
500. Kolivand S, Nazari M, Modarressi MH, Hosseini Najafabadi MR, Hemati A, **Ghafouri-Fard S**, Motevaseli E. Optimized protocol for soluble prokaryotic expression, purification and refolding of the human inhibin α subunit, a cysteine rich peptide chain. *Human Antibodies*. 2019 [accepted].
501. Safari M, Noroozi R, Taheri M, **Ghafouri-Fard S**. The rs12826786 in HOTAIR lncRNA is associated with risk of autism spectrum disorder. *Journal of Molecular Neuroscience*. 2019 [accepted].
502. **Ghafouri-Fard S**, Noroozi R, Musavi M, Taheri M. Association analysis between genomic variants within advanced glycation end product specific receptor (AGER) gene and risk of breast cancer in Iranian women. *Heliyon*. 2019 [accepted].
503. **Ghafouri-Fard S**, Azari I, Hashemian F, Nejatizadeh A, Taheri M. No association between AKT1 polymorphisms and methamphetamine addiction in Iranian population. *Journal of Molecular Neuroscience*. 2019 [accepted].
504. **Ghafouri-Fard S**, Taheri M. *UCA1* long non-coding RNA: an update on its roles in malignant behavior of cancers. *Biomedicine & Pharmacotherapy*. 2019 [accepted].
505. Ayatollahi SA, **Ghafouri-Fard S**, Noroozi R, Taheri M. The efficacy of Interferon beta-therapy in multiple sclerosis patients: investigation of the RORA gene as a predictive biomarker. *The Pharmacogenomics Journal*. 2019 [accepted].
506. Abdolmaleki F, **Ghafoui-Fard S**, Taheri M, Omrani MD. bP21-associated ncRNA DNA damage-activated expression in bladder cancer. *Klin Onkol*. 2019, 32 (4): 277-280.
507. Safari MR, Noroozi R, Omrani MD, Taheri M, **Ghafouri-Fard S**. Analysis of association between RAGE polymorphisms and stroke risk. *Meta Gene*. 2019 [accepted].
508. Toghi M, Bitarafan S, Delavar Kasmaei H, **Ghafouri-Fard S**. *Bifidobacteria*: a probable missing puzzle piece in the pathogenesis of multiple sclerosis. *Multiple Sclerosis and Related Disorders*. 2019 [accepted].
509. Esfandi F, Taheri M, Kholghi Oskooei V, Namvar A, **Ghafouri-Fard S**. GAS8 and GAS8-AS1 expression in gastric cancer. *Gastroenterology and Hepatology From Bed to Bench Journal (GHFBB)*. 2019 [accepted].

510. Fallah H, Azari I, Neishabouri SM, Kholghi Oskooei V, Taheri M, **Ghafouri-Fard S**. Sex-specific up-regulation of lncRNAs in peripheral blood of patients with schizophrenia. *Scientific Reports*. 2019 [accepted].
511. Esmacili M, Niazi V, Pourfathollah AK, Mousavi Hosseini MK, Nakhlestani M, Golzadeh K, Taheri M, **Ghafouri-Fard S**, Atarodi K. The Impact of Parathyroid Hormone Treated Mesenchymal Stem Cells on Ex-vivo Expansion of Cord Blood Hematopoietic Stem Cells. *Gene Reports*. 2019 [accepted].
512. Namvar A, Taheri M, Kahaei MS, Omrani MD, Sayad A, **Ghafouri-Fard S**. Association analysis of highly accelerated region 1A variant and risk of psychiatric conditions. *Gene Reports*. 2019 [accepted].
513. Eftekharian M, Taheri M, Arsang-Jang S, Komaki A, **Ghafouri-Fard S**. Nicotinamide Nucleotide Transhydrogenase expression analysis in multiple sclerosis patients. *International Journal of Neuroscience*. 2019 [accepted].
514. Noroozi R, Sadeghi E, Mohammadi R, Noroozi R, Dowlati A, Taheri M, **Ghafouri-Fard S**. Wound healing features of *Prosopis farcta*: in vitro evaluation of antibacterial, antioxidant, proliferative and angiogenic properties. *Gene Reports*. 2019 [accepted].
515. Mohebi M, **Ghafouri-Fard S**. Embryo Developmental Arrest: Review of Genetic Factors and Pathways. *Gene Reports*. 2019 [accepted].
516. Nafar M, Kalantari S, Omrani MD, Arsang-Jang S, Taheri M, **Ghafouri-Fard S**. Suppressor of cytokine signaling genes in renal transplant receivers: association with transplant fate. *Transplant Immunology*. 2019 [accepted].
517. Soleimani S, Nasim N, Esfandi F, Karimipoor M, Kholghi-Oskooei V, Taheri M, **Ghafouri-Fard S**. SE Translocation gene but not Zinc Finger and X-Linked Factor is down-regulated in gastric cancer. *Gastroenterology and Hepatology From Bed to Bench*. 2019 [accepted].
518. Alipour N, Salehpour S, Tonekaboni SH, Rostami M, Bahari S, Yassae V, Miryounesi M, **Ghafouri-Fard S**. Mutations in the VPS13B gene in Iranian patients with different phenotypes of Cohen syndrome. *Journal of Molecular Neuroscience*. 2019 [accepted].
519. Ebadi N, **Ghafouri-Fard S**, Taheri M, Arsang-Jang S, Arefizadeh R, Omrani MD. Expression analysis of CEBPA and its antisense RNA revealed their dysregulation in peripheral blood of coronary artery disease patients. *Gene Reports*. 2019 [accepted].
520. Khazaei M, Davoodian A, Taheri M, **Ghafouri-Fard S**. Former antiplatelet drug administration and consequences of intravenous thrombolysis in acute ischemic stroke. *Human Antibodies*. 2019 [accepted].
521. Malekzadeh V, Azari I, Noroozi R, Shams R, Khazaei M, Farzaneh M, Taheri M, **Ghafouri-Fard S**. Genetic variants within Ninjurin 2 gene are associated with risk of ischemic stroke in Iranian population. *Neurological Sciences*. 2019 [accepted].

522. Soltani N, Yazarlou F, Akhondi MM, Sobhani M, Modarressi MH, **Ghafouri-Fard S**. *TSGA10* polymorphisms are not associated with male infertility in Iranian population. *Gene Reports*. 2019 [accepted].
523. Eftekharian MM, Komaki A, Kholghi Oskooie V, Namvar A, Taheri M, **Ghafouri-Fard S**. Assessment of apoptosis pathway in peripheral blood of autistic patients. *Journal of Molecular Neuroscience*. 2019 [accepted].
524. Ravesh Z, Yassaee VR, Tonekaboni SH, Razzaghy-Azar M, Hashemi-Gorji F, Salehpour S, Miryounesi M, **Ghafouri-Fard S**. Next Generation Sequencing Elucidated a Clinically Undiagnosed Metabolic Disorder- an Iranian family with Hereditary Orotic Aciduria. *Gene Reports*. 2019 [accepted].
525. Noroozi R, Azari I, Taheri M, Omrani MD, **Ghafouri-Fard S**. A single nucleotide polymorphism within *Ninjurin 2* is associated with risk of multiple sclerosis. *Metabolic Brain Disease*. 2019 [accepted].
526. Sobhani M, Tabatabaiefar MA, **Ghafouri-Fard S**, Rajab A, Mozafarpour S, Nasrniya S, Kajbafzadeh A, Noori-Dalooi MR. Clinical and Molecular Assessment of 13 Iranian Families with Wolfram Syndrome. *Endocrine*. 2019 [accepted].
527. **Ghafouri-Fard S**, Kholghi Oskooei V, Omrani MD, Taheri M. Dysregulation of cytokine coding genes in peripheral blood of bipolar patients. *Journal of Affective Disorders*. 2019 [accepted].
528. Khazaei M, Karevan A, Taheri M, **Ghafouri-Fard S**. Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis. *Clinical and Translational Medicine*. 2019 [accepted].
529. Rakhshan A, Taheri M, Omrani MD, Noroozi R, **Ghafouri-Fard S**. A single nucleotide polymorphism in *GAS5* lncRNA is associated with risk of bladder cancer in Iranian population. *Pathology and Oncology Research*. 2019 [accepted].
530. **Ghafouri-Fard S**, Taheri M. *Maternally expressed gene 3 (MEG3)*: a tumor suppressor long non coding RNA. *Biomedicine and pharmacotherapy*. 2019 [accepted].
531. **Ghafouri-Fard S**, Mir Davood Omrani, Mohammad Taheri. Long non-coding RNA *PVT1*: a highly dysregulated gene in malignancy. *Journal of Cellular Physiology*. 2019 [accepted].
532. Eftekharian MM, Komaki A, Omrani MD, Arsang-Jang S, Ganji M, Taheri M, **Ghafouri-Fard S**. Expression analysis of cytokine coding genes in blood samples of clozapine-treated patients with schizophrenia. *Clinical and Experimental Neuroimmunology*. 2019 [accepted].
533. Yaghoobi H, Azizi H, Banitalebi-Dehkordi M, Arsang-Jang S, Kholghi Oskooei V, Taheri M, **Ghafouri-Fard S**. *Beta-secretase 1 (BACE1)* is down-regulated in invasive ductal carcinoma of breast. *Reports of Biochemistry and Molecular Biology*, 2019 [accepted].

534. Esfandi F, Taheri M, Kahaei M, Omrani MD, Kholghi Oskooei V, **Ghafouri-Fard S**. Down-regulation of Nicotinamide Nucleotide Transhydrogenase and its naturally occurring antisense RNA in gastric cancer. *Asia Pacific Journal of Clinical Oncology*, 2019 [accepted].
535. Miryounesi M, Bahari S, Salehpour S, Alipour N, **Ghafouri-Fard S**. ELMO Domain Containing 1 (ELMOD1) gene mutation is associated with mental retardation and autism spectrum disorder. *Journal of Molecular Neuroscience*, 2019 [accepted].
536. Pouresmaeili F, Azari I, Arsang-Jang S, Taheri M, **Ghafouri-Fard S**. Association between expression of long non-coding RNAs in placenta and pregnancy features. *Personalized Medicine*, 2019 [accepted].
537. Noroozi R, Taheri M, Omrani MD, **Ghafouri-Fard S**. Glutamate receptor metabotropic 7 (GRM7) gene polymorphisms in mood disorders and attention deficit hyperactive disorder. *Neurochemistry International*. 2019 [accepted].
538. Mazdeh M, Noroozi R, Komaki A, Taheri M, **Ghafouri-Fard S**. Single nucleotide polymorphisms of lncRNA H19 are not associated with risk of multiple sclerosis in Iranian population. *Meta Gene*. 2019 [accepted].
539. Mazdeh M, Zamani M, Eftekharian M, Komaki A, Arsang-Jang S, Taheri M, **Ghafouri-Fard S**. Expression analysis of vitamin D receptor-associated lncRNAs in epileptic patients. *Metabolic Brain Disease*. 2019 [accepted].
540. Salek Esfahani B, Gharesouran J, **Ghafouri-Fard S**, Talebian S, Arsang-Jang S, Omrani, Taheri M, Rezazadeh M. Down-Regulation of ERMN Expression in Relapsing Remitting Multiple Sclerosis. *Metabolic Brain Disease*. 2019 [accepted].
541. Nasim N, Soleimani S, Esfandi F, Raheb J, Shirkhoda M, Safaei M, Kholghi Oskooei V, Ghafouri-Fard S, Taheri M. Assessment of SGO1 and SGO1-AS1 contribution in breast cancer. *Human Antibodies*. 2019 [accepted].
542. Abdolmaleki F, **Ghafoui-Fard S**, Taheri M, Mordadi A, Afasharpad M, Varmazyar S, Nazparvar B, Kholghi Oskooei V, Omrani MD. Expression analysis of a panel of long non-coding RNAs (lncRNAs) revealed their potential as diagnostic biomarkers in bladder cancer. *Genomics*. 2019 [accepted].
543. Shams R, Dianatpour A, Omrani MD, **Ghafouri-Fard S**. Expression analysis of miR-100 and selected genes from mTOR pathway in breast cancer patients. *Meta Gene*. 2019 [accepted].
544. Astaneh M, **Ghafouri-Fard S**. Long non-coding RNAs as regulators of Wnt/ β catenin pathway. *Gene Reports*. 2019 [accepted].
545. Esfandi F, Bouraghi H, Glassy MC, Taheri M, Kahaei MS, Khloghi-Oskooei V, **Ghafouri-Fard S**. Brain-derived neurotrophic factor down-regulation in gastric cancer. *Journal of Cellular Biochemistry*. 2019 [accepted].

546. Taherian-Esfahani Z, Taheri M, Dashti S, Kholghi-Oskooei V, Geranpayeh L, **Ghafouri-Fard S**. Assessment of expression pattern of mTOR-associated lncRNAs and their genomic variants in breast cancer patients. *Journal of Cellular Physiology*. 2019 [accepted].
547. Dashti S, Taherian-Esfahani Z, Keshtkar A, **Ghafouri-Fard S**. Associations between XRCC3 Thr241Met polymorphisms and breast cancer risk: Systematic-review and meta-analysis of 55 case-control studies. *BMC Medical Genetics*. 2019 [accepted].
548. Sayad A, Taheri M, Arsang-Jang S, Glassy M, **Ghafouri-Fard S**. Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA: a Putative Marker in Multiple Sclerosis. *Metabolic Brain Disease*. 2019 [accepted].
549. Pathoughy M, **Ghafouri-Fard S**, Arsang-Jang S, Taheri M. GAS8 and its naturally occurring antisense RNA as biomarkers in multiple sclerosis. *Immunobiology*. 2019 [accepted].
550. Safari MR, Noroozi R, Mazdeh M, Taheri M, **Ghafouri-Fard S**. *RAGE* polymorphisms are not associated with risk of multiple sclerosis in Iranian population. *Gene Reports*. 2019 [accepted].
551. Esfandi F, Taheri M, Namvar A, Kholghi Oskooei V, **Ghafouri-Fard S**. *AFAP1* and its naturally occurring antisense RNA are down-regulated in gastric cancer samples. *Biomedical Reports*. 2019 [accepted].
552. **Ghafouri-Fard S**, ..., Taheri M, Omrani MD. Application of single nucleotide polymorphisms in the diagnosis of autism spectrum disorders: a preliminary study with artificial neural networks. *Journal of Molecular Neuroscience*. 2019 [accepted].
553. Shams R, Seifi-Alan M, Bandehpour M, Omrani MD, **Ghafouri-Fard S**. C-X-C chemokine receptor type 7 (CXCR-7) expression in invasive ductal carcinoma of breast in association with clinicopathological features. *Pathology and Oncology Research*. 2019 [accepted].
554. Safari M, Mohammad Rezaei F, Dehghan A, Noroozi R, Taheri M, **Ghafouri-Fard S**. Genomic variants within the long non-coding RNA H19 confer risk of breast cancer in Iranian population. *Gene*. 2019 [accepted].
555. Mirtavoos-Mahyari H, **Ghafouri-Fard S**, Khosravi A, Motevaseli E, Esfahani-Monfared Z, Seifi S, Salimi B, Kholghi Oskooei V, Ghadami M, Modarressi MH. Circulating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer. *Clinical and Translational Medicine*. 2019 [accepted].
556. Mazdeh M, Kargar Monhaser S, Taheri M, **Ghafouri-Fard S**. A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients. *Clinical and Translational Medicine*. 2019 [accepted].
557. **Ghafouri-Fard S**, Taheri M, Kholghi Oskooei V, Omrani MD. Gender-based dimorphisms in expression of BDNF and BACE1 in bipolar patients. *Comprehensive Psychiatry*. 2019 [accepted].
558. Eftekharian MM, Komaki A, Mazdeh M, Arsang-Jang S, Taheri M, **Ghafouri-Fard S**. Expression profile of selected microRNAs in the peripheral blood of multiple sclerosis patients: A multivariate

- statistical analysis with ROC curve to find new biomarkers for Fingolimod. *Journal of Molecular Neuroscience*. 2019 [accepted].
559. Esfandi F, Taheri M, Omrani MD, Behgam Shadmehr M, Arsang-Jang S, Shams R, **Ghafouri-Fard S**. Expression of long non-coding RNAs (lncRNAs) has been dysregulated in non-small cell lung cancer tissues. *BMC Cancer*. 2019 [accepted].
560. Taheri M, Kholghi Oskooei V, **Ghafouri-Fard S**. *Protein inhibitor of activated STAT (PIAS)* genes are differentially expressed in breast tumor tissues. *Personalized Medicine*. 2019 [accepted].
561. **Ghafouri-Fard S**, Taheri M. Growth arrest specific transcript 5 in tumorigenesis process: an update on the expression pattern and genomic variants. *Biomedicine and Pharmacotherapy*. 2019 [accepted].
562. Kobarfard F, Noroozi R, Dowlati Beirami A, Taheri M, **Ghafouri-Fard S**. Dys-regulation of peripheral transcript levels of ecto-5'-nucleotidase in multiple sclerosis patients. *Human Antibodies*. 2019 [accepted].
563. **Ghafouri-Fard S**, Vafae R, Taheri M. Taurine upregulated gene 1: a functional long non-coding RNA in tumorigenesis. *Journal of Cellular Physiology*, 2019 [accepted].
564. Esfandi F, **Ghafouri-Fard S**, Kholghi Oskooei V, Taheri M. β -secretase 1 and its naturally occurring anti-sense RNA are down-regulated in gastric cancer. *Pathology and Oncology Research*, 2019 [accepted].
565. Sayad A, Akbari MT, Inoko H, Khazaei M, Mehdizadeh B, Taheri M, **Ghaforui-Fard S**. Association between HLA alleles and risk of stroke in Iranian population. *International Journal of Immunogenetics*, 2019 [accepted].
566. Afshar D, **Ghafouri-Fard S**, Hejazi MA, Barzegarid A, Eslami S. Polyphasic characterization of *Enterococcus* strains isolated from traditional Moghan cheese in Iran. *Journal of Food Safety*, 2019 [accepted].
567. Eftekharian MM, Noroozi R, Komaki A, Mazdeh M, Taheri M, **Ghafouri-Fard S**. *GAS5* genomic variants and risk of multiple sclerosis. *Neuroscience Letters*, 2019 [accepted].
568. **Ghafouri-Fard S**, Taheri M, Omrani MD, Kholghi Oskooei V. Expression of long non-coding RNAs in breast cancer in relation to reproductive factors and tumor characteristics. *Journal of Cellular Biochemistry*, 2019 [accepted].
569. Hajiesmaeil M, Yazarlou F, Sobhani M, **Ghafouri-Fard S**. A new mutation in NTRK1 gene is associated with congenital insensitivity to pain without anhidrosis. *Meta Gene*, 2019 [accepted].
570. Khazaei M, Hosseini Nejad Mir N, Yadranji Aghdam F, Taheri M, **Ghafouri-Fard S**. Effectiveness of intravenous dexamethasone, metoclopramide, ketorolac and chlorpromazine for pain relief and prevention of recurrence in the migraine headache: a prospective double blind randomized clinical trial. *Neurological Sciences*. 2019 [accepted].

571. Khazaei M, Ghasemian F, Mazdeh M, Taheri M, **Ghafouri-Fard S**. Comparison of administration of clopidogrel with aspirin versus aspirin alone in prevention of secondary stroke after transient ischemic attack. *Clinical and Translational Medicine*. 2019 [accepted].
572. Sayad A, Taheri M, Omrani MD, Fallah H, Kholghi Oskooei V, **Ghafouri-Fard S**. Peripheral expression of long non-coding RNAs in bipolar patients. *Journal of affective disorders*. 2019 [accepted].
573. Talebian S, Gharesouran J, **Ghafouri-Fard S**, Salek Esfahani B, Arsang-Jang S, Omrani MD, Taheri M, Rezazadeh M. Assessment of expression of RELN signaling pathway in multiple sclerosis patients. *Immunobiology*. 2019 [accepted].
574. Seifi-Alan M, Dianatpour A, Geranpayeh L, Mirfakhraie R, Omrani MD, **Ghafouri-Fard S**. Expression analysis of selected miR-206 targets from transforming growth factor (TGF)- β signaling pathway in breast cancer. *Journal of Cellular Biochemistry*. 2019 [accepted].
575. Mirzaei A, Saburi E, Islami M, Ardeshirylajimi A, Omrani MD, Taheri M, Shapouri Moghadam A, **Ghafouri-Fard S**. Bladder smooth muscle cell differentiation of the human induced pluripotent stem cells on electrospun Poly(lactide-co-glycolide) nanofibrous structure. *Gene*. 2019 [accepted].
576. Eftekharian M, Noroozi R, Komaki A, Mazdeh M, **Ghafouri-Fard S**, Taheri M. MALAT1 genomic variants and risk of multiple sclerosis. *Immunological Investigations*. 2019 [accepted].
577. Mazdeh M, Eftekharian M, Komaki A, Arsang-Jang S, **Ghafouri-Fard S**, Taheri M. Long noncoding RNA AFAP1-AS1 is up-regulated in a subset of multiple sclerosis patients. *Clinical and Experimental Neuroimmunology*. 2019 [accepted].
578. Khazaei M, Khosravi M, Mazaheri S, Mazdeh M, Ghiasian M, Taheri M, **Ghafouri-Fard S**. The effect of atorvastatin on intima-media thickness of the common carotid artery in patients with ischemic stroke. *ACTA CLINICA CROATICA*. 2019 [accepted].
579. Sayad A, Taheri M, Azari I, Kholghi Oskoei V, **Ghafouri-Fard S**. *PLAS* genes as disease markers in bipolar disorder. *Journal of Cellular Biochemistry*. 2019 [accepted].
580. **Ghafouri-Fard S**, Taheri M. Colon Cancer Associated Transcripts 1 and 2: Roles and Functions in Human Cancers. *Journal of Cellular Physiology*. 2019 [accepted].
581. Omrani S, Taheri M, Omrani MD, Arsang-Jang S, **Ghafouri-Fard S**. The effect of omega-3 fatty acids on clinical and paraclinical features of intractable epileptic patients: a triple blind randomized clinical trial. *Clinical and Translational Medicine*. 2019 [accepted].
582. Taheri M, Noroozi R, Dehghan A, Atri Roozbahani G, Omrani MD, **Ghafouri-Fard S**. Interleukin (IL)-8 polymorphisms and risk of prostate disorders. *Gene*. 2019 [accepted].
583. Mazdeh M, Noroozi R, Komaki A, Azari I, **Ghafouri-Fard S**, Taheri M. A single nucleotide polymorphism in the metabotropic glutamate receptor 7 gene is associated with multiple sclerosis in Iranian population. *Multiple Sclerosis and Related Disorders*. 2019 [accepted].

584. Esfandi F, Taheri M, Kholghi Oskooei V, **Ghafouri-Fard S**. Long non-coding RNAs expression in gastric cancer. *Journal of Cellular Biochemistry*. 2019 [accepted].
585. Dianatpour A, Faramarzi S, **Ghafouri-Fard S**. Meta-analysis of association between BRIP1 polymorphisms and breast cancer risk. *International Journal of Cancer Management*. 2018 [accepted].
586. Azari I, Hosseinpour Moghadam R, Fallah H, Noroozi R, **Ghafouri-Fard S**, Taheri M. GRM7 polymorphisms and risk of schizophrenia in Iranian population. *Metabolic Brain Disease*. 2018 [accepted].
587. Abdolmaleki F, **Ghafoui-Fard S**, Taheri M, Mordadi A, Afasharpad M, Nikfallah A, Nazparvar B, Kholghi Oskooei V, Omrani MD. Expression analysis of OIP5-AS1 in bladder tissues. *Genetics and Molecular Research*. 2018 [accepted].
588. Gharesouran J, Taheri M, Sayad A, **Ghafouri-Fard S**, Mazdeh M, Omrani MD. A novel regulatory function of long non-coding RNAs at different levels of gene expression in multiple sclerosis. *Journal of Molecular Neuroscience*. 2018 [accepted].
589. Shams R, Geranpayeh L, Omrani MD, **Ghafouri-Fard S**. Expression analysis of *Inhibitor Of DNA Binding 1 (ID-1)* gene in breast cancer. *Human Antibodies*. 2018 [accepted].
590. **Ghafouri-Fard S**, Taheri M. Nuclear Enriched Abundant Transcript 1 (NEAT1): a long non-coding RNA with diverse functions in tumorigenesis. *Biomedicine & Pharmacotherapy*. 2018 [accepted].
591. Sayad A, Omrani MD, Fallah H, Taheri M, **Ghafouri-Fard S**. Aberrant expression of long non-coding RNAs in peripheral blood of autistic patients. *Journal of Molecular Neuroscience*. 2018 [accepted].
592. Safari MR, Komaki A, Arsang-Jang S, Taheri M, **Ghafouri-Fard S**. Expression pattern of long non-coding RNAs in schizophrenic patients. *Cellular and Molecular Neurobiology*. 2018 [accepted].
593. Esfandi F, Mir Hassani Z, Arsang-Jang S, Taheri M, **Ghafouri-Fard S**. Expression analysis of long non-coding RNAs *GSTT1-AS1* and *IFNG-AS1* and their target genes in lung cancer. *Genetics and Molecular Research*. 2018 [accepted].
594. Mazdeh M, Hosseini S, Taheri M, **Ghafouri-Fard S**. The effect of Natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study. *Clinical and Translational Medicine*. 2018 [accepted].
595. **Ghafouri-Fard S**, Taheri M, Kholghi Oskooie V, Omrani MD, Sayad A. *NNT* and *NNT-AS1* expression levels are not different between bipolar patients and healthy subjects. *Genetics and Molecular Research*. 2018 [accepted].
596. Rakhshan A, Omrani MD, Noroozi R, Taheri M, **Ghafouri-Fard S**. Retinoic Acid Related Orphan Receptor A (RORA) gene variants and risk of bladder cancer. *Gene Reports*. 2018 [accepted].

597. **Ghafouri-Fard S**, Kholghi Oskooei V, Azari I, Taheri M. *Suppressor of Cytokine Signaling (SOCS)* genes are down-regulated in breast cancer. *World Journal of Surgical Oncology*. 2018 [accepted].
598. Sayad A, Akbari MT, Noroozi R, Omrani MD, Inoko H, Taheri M, **Ghafouri-Fard S**. The association of HLA alleles with autism. *Neuropsychiatric Disease and Treatment*. 2018 [accepted].
599. Taheri M, Azimi G, Sayad A, Mazdeh M, Arsang-Jang S, Omrani MD, **Ghafori-Fard S**. Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFN β -treated multiple sclerosis patients. *Journal of Inflammation Research*. 2018 [accepted].
600. Dastmalchi R, Sayad A, Omrani MD, **Ghafouri-Fard S**, Arsang-Jang S, Mazdeh M, Taheri M. Investigation of the role of apoptosis, necroptosis and DNA damage signaling pathways in multiple sclerosis. *Genetics and Molecular Research*. 2018 [accepted].
601. Taherian Esfahani Z, Dashti S, Taheri M, Kholghi-Oskooei V, Arsang-Jang S, **Ghafouri-Fard S**. Expression of brain-derived neurotrophic factor (*BDNF*) and its naturally occurring antisense in breast cancer samples. *Meta Gene*, 2018 [accepted].
602. Yazarlou F, Modarressi MH, Mowla SJ, Kholghi Oskooei V, Motevaseli E, Farhady Tooli L, Nekooohesh L, Eghbali M, **Ghafouri-Fard S**, Afsharpad M. Urinary exosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer. *Cancer Management and Treatment*, 2018 [accepted].
603. Ganji M, Dastmalchi R, Sayad A, Omrani MD, Mazdeh M, Taheri M, **Ghafouri-Fard S**. Expression analysis of β -secretase (*BACE1*) and its naturally occurring anti-sense (*BACE1-AS*) in multiple sclerosis. *Gene Reports*. 2018 [accepted].
604. Khorshidi H, Azari I, Kholghi Oskooei V, **Ghafouri-Fard S**, Taheri M. *DSCAM-AS1* up-regulation in invasive ductal carcinoma of breast and assessment of its potential as a diagnostic biomarker. *Breast Disease*. 2018 [accepted].
605. Yaghoobi H, Azizi H, Kholghi Oskooei V, Taheri M, **Ghafouri-Fard S**. Assessment of expression of *interferon γ* (*IFN-G*) gene and its antisense (*IFNG-AS1*) in breast cancer. *World Journal of Surgical Oncology*. 2018 [accepted].
606. Kholghi Oskooei V, **Ghafouri-Fard S**. Are long non-coding RNAs involved in the interaction circuit between estrogen receptor and vitamin D receptor? *Meta Gene*. 2018 [accepted].
607. Ravesh Z, **Ghafouri-Fard S**, Rostami M, Alipour N, Yassaee V, Miryounesi M. Whole exome sequencing unraveled the mystery of neurodevelopmental disorders in three Iranian families. *Gene Reports*. 2018 [accepted].
608. Nouri Z, Neyazi N, Modarressi MH, Karami F, Abedin-Do A, Taherian-Esfahani Z, Ghafouri-Fard S, Motevaseli E. Down-regulation of *TSGA10*, *AURKC*, *OIP5* and *AKAP4* genes by *Lactobacillus rhamnosus* GG and *Lactobacillus crispatus* SJ-3C-US supernatants in HeLa cell line. *Klinická onkologie*. 2018 [accepted].

609. Eftekharian MM, Omrani MD, Komaki A, Arsang-Jang S, Taheri M, **Ghafouri-Fard S**. Expression analysis of *suppressor of cytokine signaling (SOCS)* genes in blood of autistic patients. *Advances in Neuroimmune Biology*, 2018 [accepted].
610. Yazarlou F, Mowla SJ, Kholghi Oskooei V, Motevaseli E, Farhady Tooli L, Afsharpad M, Nekoohesh L, Sanikhani NS, **Ghafouri-Fard S**, Modarressi MH. Urine exosome gene expression of cancer-testis antigens for prediction of bladder carcinoma. *Cancer Management and Treatment*, 2018 [accepted].
611. Saleh Gargari S, Taheri M, Kholghi Oskooie V, Omrani MD, **Ghafouri-Fard S**. Transcript levels of long non-coding RNA Nicotinamide Nucleotide Transhydrogenase-antisense RNA1 (*NNT-AS1*) in breast cancer samples. *Cell Journal*, 2018 [accepted].
612. Taheri M, Noroozi R, Rakhshan A, Ghanbari M, Omrani MD, **Ghafouri-Fard S**. IL-6 genomic variants and risk of prostate cancer. *Urology Journal*, 2018 [accepted].
613. Eftekharian MM, Noroozi R, Omrani MD, Sharifi Z, Komaki A, Taheri M, **Ghafouri-Fard S**. Single nucleotide polymorphisms in *Interleukin 6 (IL-6)* gene are associated with suicide behavior in an Iranian population. *Journal of Molecular Neuroscience*, 2018 [accepted].
614. Yaeghmaie R, **Ghafouri-Fard S**, Noroozi R, Tavakoli F, Taheri M, Ayatollahi SA. Polymorphisms in the *angiotensin I converting enzyme (ACE)* gene are associated with multiple sclerosis risk and response to Interferon- β treatment. *International Immunopharmacology*, 2018 [accepted].
615. Yazarlou F, Afsharpad M, Kholghi Oskooei V, Nekoohesh L, Moharrami T, Samadaian N, **Ghafouri-Fard S**, Modarressi MH. Expression analysis of apoptosis-related genes in bladder cancer patients. *MetaGene*, 2018 [accepted].
616. Esfandi F, Omrani MD, Fallah H, Arsang-Jang S, Taheri M, **Ghafouri-Fard S**. Expression of *CCAT2*, *UCA1*, *PANDA* and *GHET1* lncRNAs in lung cancer. *Reports of Biochemistry and Molecular Biology*, 2018 [accepted].
617. Asadzadeh Manjili F, Kalantar SM, Arsang-Jang S, **Ghafouri-Fard S**, Taheri M, Sayad A. Up-regulation of vitamin D related genes in schizophrenic patients. *Neuropsychiatric Disease and Treatment*, 2018 [accepted].
618. Zhand A, Sayad A, **Ghafouri-Fard S**, Arsang-Jang S, Taheri M. Expression analysis of *GRIN2B*, *BDNF* and *IL-1 β* genes in the whole blood of epileptic patients, *Neurological Sciences*, 2018 [accepted].
619. Dianatpour A, Faramarzi S, **Ghafouri-Fard S**. Meta-analysis of association between *PALB2* polymorphisms and breast cancer. *Asian Pacific Journal of Cancer Prevention*, 2018 [accepted].
620. Noroozi R, Omrani MD, Ayatollahi SA, Sayad A, Ata A, Fallah H, Taheri M, **Ghafouri-Fard S**. Interleukin (IL)-8 polymorphisms contribute in suicide behavior. *Cytokine*, 2018 [accepted].
621. Nekoohesh L, Modarressi MH, Mowla SJ, Sadroddiny E, Etemadian M, Afsharpad M, Zolfaghari F, Barzegari M, Saffari M, Kholghi Oskooei V, Motevaseli E, **Ghafouri-Fard S**. Expression profile of miRNAs in urine samples of bladder cancer patients. *Biomark Med*. 2018 [accepted].
622. Dastmalchi R, **Ghafouri-Fard S**, Omrani MD, Mazdeh M, Sayad A, Taheri M. Dysregulation of long non-coding RNA profile in peripheral blood of multiple sclerosis patients. *Multiple Sclerosis and Related Disorders*. 2018 [accepted].

623. Eftekharian MM, Noroozi R, Omrani MD, Arsang-Jang S, Komaki A, Taheri M, **Ghafouri-Fard S**. Expression analysis of *protein inhibitor of activated STAT (PLAS)* genes in autistic patients. *Advances in Neuroimmune Biology*. 2018 [accepted].
624. Yazarloo F, Kholghi Oskooei V, Afsharpad M, Nekoohesh L, Moharrami T, Motahary Rad H, **Ghafouri-Fard S**, Modarressi MH. Expression analysis of a panel of cancer-testis antigens in bladder cancer. *Personalized Medicine*. 2018 [accepted].
625. Sayad A, **Ghafouri-Fard S**, Noroozi R, Omrani MD, Ganji M, Dastmalchi R, Taheri M. Association Study of Sequence Variants in Voltage-Gated Ca²⁺ Channel Subunit alpha-1 C and Autism Spectrum Disorders in an Iranian Population. *Reports of Biochemistry and Molecular Biology*. 2018 [accepted].
626. Kholghi Oskooei V, Geranpayeh L, Omrani MD, **Ghafouri-Fard S**. Assessment of functional variants and expression of long non-coding RNAs in vitamin D receptor signaling in breast cancer. *Cancer Management and Research*, 2018 [accepted].
627. Dianatpour A, Faramarzi S, **Ghafouri-Fard S**. Meta-analysis of *BRC A1* polymorphisms and breast cancer susceptibility. *Klinická onkologie*. 2018 [accepted].
628. Azari I, **Ghafouri-Fard S**, Omrani MD, Arsang-Jang S, Kordi Tamandani DM, Saroone Rigi M, Rafiee S, Poursmaeili F, Taheri M. Expression of Long non-coding RNAs in placenta of IUGR pregnancies. *Reports of Biochemistry and Molecular Biology*. 2018 [accepted].
629. Noroozi R, Taheri M, **Ghafouri-Fard S**, Bidel Z, Omrani MD, Sanjari Moghaddam A, Sarabi P, Mosavi Jarahi A. Meta-analysis of *GABRB3* gene polymorphisms and susceptibility to Autism Spectrum Disorder. *Journal of Molecular Neuroscience*. 2018 [accepted].
630. Sayad A, Ranjbaran F, **Ghafouri-Fard S**, Arsang-Jang S, Taheri M. Expression analysis of *CYFIP1* and *CAMKK2* genes in the blood of epileptic and schizophrenic patients. *Journal of Molecular Neuroscience*. 2018 [accepted].
631. Eftekharian M, Omrani MD, Arsang-Jang S, Taheri M, **Ghafouri-Fard S**. Serum cytokine profile in schizophrenic patients. *Human Antibodies*. 2018 [accepted].
632. Taheri M, **Ghafouri-Fard S**. Long non-coding RNA signature in cervical cancer. *Klinická onkologie*. 2018 [accepted].
633. Esfandi F, Kholghi Oskooei V, Taheri F, Kiani A, Taheri M, **Ghafouri-Fard S**. Expression analysis of *OIP5-AS1* in non-small cell lung cancer. *Klinická onkologie*. 2018 [accepted].
634. **Ghafouri-Fard S**, Hejazi M, Afshar D, Barzegari A, Eslami S. 16S-Amplified Ribosomal DNA Restriction Analysis Assay for Discriminating Potentially Probiotic Lactobacillus Species Isolated From Traditional Dairy Products. *Journal of Kerman University of Medical Sciences*, 2018 [accepted].

635. Mazdeh M, Komaki A, Omrani MD, Sayad A, Taheri M, **Ghafouri-Fard S**. Expression analysis of beta-secretase (*BACE1*) and its naturally occurring antisense (*BACE1-AS*) in blood of epileptic patients, *Neurological Sciences*, 2018 [accepted].
636. Taheri M, **Ghafouri-Fard S**. Antisense non-coding RNA in the INK4 locus (*ANRIL*) in human cancers. *International Journal Cancer Management*, 2018 [accepted].
637. Faramarzi S, Dianatpour A, Geranpayeh L, Mirfakhraie R, Shamsi R, Seifi-Alan M, Kholghi Oskoei V, **Ghafouri-Fard S**. Expression analysis of CBR3-AS1 and androgen receptor genes in breast cancer, *Meta Gene*, 2018 [accepted].
638. Seifi-Alan M, Shamsi R, Bandehpour M, Mirfakhraie R, **Ghafouri-Fard S**. Neuropilin-1 expression is associated with lymph node metastasis in breast cancer tissues. *Cancer Management and Research*, 2018 [accepted].
639. Sayad A, Salmani T, Kazemzadeh Hemmesi M, Ganji M, **Ghafouri-Fard S**, Hatami M, Soudyab M, Taheri M. Down-regulation of RORA gene expression in the blood of Multiple Sclerosis patients. *Human Antibodies*, 2018 [accepted].
640. Younesi S, Savad S, **Ghafouri-Fard S**, Taheri-Amin MM, Saadati P, Jamali S, Balvayeh P, Delshad S, Navidpour F, Adiban F, Amidi S, Modarressi MH. First and second-trimester contingent screening for trisomy 21 by fetal nuchal translucency and maternal serum biomarkers and maternal blood cell-free DNA testing. *Journal of Fetal Medicine*, 2018 [accepted].
641. Seifi-Alan M, Shamsi R, Behmanesh A, Mirfakhraie R, Omrani MD, **Ghafouri-Fard S**. miR-206 target prediction in breast cancer subtypes by bioinformatics tools. *International Journal Cancer Management*, 2018 [accepted].
642. Kholghi Oskoei V, **Ghafouri-Fard S**, Omrani MD. A combined bioinformatics and literature based approach for identification of long non-coding RNAs that modulate vitamin D receptor signaling in breast cancer. *Klinická onkologie*. 2018 [accepted].
643. Noroozi R, Omrani MD, Sayad A, Taheri M, **Ghafouri-Fard S**. Cytoplasmic FMRP interacting protein 1/2 (*CYFIP1/2*) expression analysis in autism. *Metabolic Brain Dis*, 2018 [accepted].
644. Shamsi R, **Ghafouri-Fard S**. No association between expression of RAS Guanyl Releasing Protein 3 (*RASGRP3*) in breast cancer and clinicopathological data. *International Journal of Cancer Management*, 2018 [accepted].
645. Iranpour M, Nourian M, Saffari S, Samizadeh E, Mirghafori M, Iravani S, **Ghafouri-Fard S**. PIK3CA mutation analysis in Iranian patients with gastric cancer. *Iranian Biomedical Journal*, 2018 [accepted].
646. Heidary H, Pouresmaeili F, Mirfakhraie R, Omrani MD, Ghaedi H, Fazeli Z, Sayban S, **Ghafouri-Fard S**, Azargashb E, Shokri F. An Association Study between Longitudinal Changes of Leukocyte Telomere and the Risk of Azoospermia in a Population of Iranian Infertile Men. *Iranian Biomedical Journal* 22 (4): 231-236.

647. Taheri M, Noroozi R, Dehghan A, Atri Roozbahani G, Musavi M, Omrani MD, **Ghafouri-Fard S**. Association study of Retinoic Acid Related Orphan Receptor A (RORA) gene and risk of prostate disorders, *Urology J*, 2018 [accepted].
648. Rezazadeh M, Gharesouran J, Moradi M, Noroozi R, Omrani MD, Taheri M, **Ghafouri-Fard S**. Association study of ANRIL genetic variants and multiple sclerosis. *Journal of Molecular Neuroscience*, 2018 [accepted].
649. Gharesouran J, Taheri M, Sayad A, **Ghafouri-Fard S**, Mazdeh M, Omrani MD. The growth arrest-specific transcript 5 (GAS5) & Nuclear Receptor Subfamily 3 Group C Member 1 (NR3C1): novel markers involved in multiple sclerosis. *IJMCM*. 2018 [accepted].
650. Faramarzi S, Dianatpour A, **Ghafouri-Fard S**. Association of *BRCA2* variants with breast cancer risk: a meta-analysis. *Meta Gene*, 2018 [accepted].
651. Eftekharian MM, **Ghafouri-Fard S**, Noroozi R, Omrani MD, Arsang-jang S, Ganji M, Gharzi V, Noroozi H, Komaki A, Mazdeh M, Taheri M, Cytokine profile in autistic patients. *Cytokine*, 2018 [accepted].
652. Kamalidehghan B, **Ghafouri-Fard S**, Motevaseli E, Ahmadipour F, Yousef Ibrahim M. Inhibition of PC-3 human prostate cancer cells and targeting of PC-3-derived prostate cancer stem cells with Koenimbin, a natural dietary compound from *Murraya koenigii* (L) Spreng. *Drug Design, Development and Therapy*, 2018 [accepted].
653. **Ghafouri-Fard S**, Yassaee VR, Alipour N, Ravesh Z, Miryounesi. A new mutation in steroidogenic acute regulatory protein (StAR) is segregated in an Iranian family. *Meta Gene*, 2018 [accepted].
654. Mazdeh M, **Ghafouri-Fard S**, Hatami M, Eftekharian MM, Ganji M, Sayad A, Arsang-Jang S, Taheri M, Omrani MD. Expression analysis of vitamin D signaling pathway genes in epileptic patients. *Journal of Molecular Neuroscience*, 2018 [accepted].
655. Taheri M, **Ghafouri-Fard S**, Sayad A, Arsang-Jang S, Mazdeh M, Toghi M, Omrani MD. Assessment of protein prenylation pathway in multiple sclerosis patients. *Journal of Molecular Neuroscience*, 2018 [accepted].
656. Nafisi-Far N, **Ghafouri-Fard S**, Tabatabaei Panah AS, Sayad A, Taheri M. A gender dimorphism in up-regulation of *BACE1* gene expression in schizophrenia. *Metabolic Brain Disease*, 2018 [accepted].
657. Sayad A, Noroozi R, Khodamoradi Z, Omrani MD, Taheri M, **Ghafouri-Fard S**. Association study of *VMAT1* polymorphisms and suicide behavior. *Journal of Molecular Neuroscience*, 2018 [accepted].
658. Miryounesi M, Tabei SMB, Dianatpour M, Fardaei M, **Ghafouri-Fard S**. Report of three cases with hereditary spastic paraplegia and investigation of the mutations. *Meta Gene*, 2018 [accepted].
659. Tasharrofi B, **Ghafouri-Fard S**. Long non-coding RNAs as regulators of the mitogen-activated protein kinase (MAPK) pathway in cancer. *Klinická onkologie*. 2018 [accepted].

660. Rahimi M, Aghabozorg Afjeh S, Omrani MD, Arsang-Jang S, Ganji M, Noroozi R, Taheri M, **Ghafouri-Fard S**. Soluble receptor for advanced glycation end products (sRAGE) is up-regulated in multiple sclerosis patients treated with Interferon β -1a. *Cellular Physiology and Biochemistry*. 2018 [accepted].
661. Mazdeh M, Omrani MD, Komaki A, Eftekharian M, Arsang-Jang S, Sayad A, Taheri M, **Ghafouri-Fard S**. Expression analysis of cytokine coding genes in epileptic patients. *Cytokine*. 2018 [accepted].
662. Dianatpour A, Faramarzi S, Geranpayeh L, Mirfakhraie R, Motevaseli E, **Ghafouri-Fard S**. Expression analysis of AFAP1-AS1 and AFAP1 in breast cancer. *Cancer Biomarkers*. 2018 [accepted].
663. Ebadi N, Javadi S, Salmani T, Miryounesi M, Yassae V, **Ghafouri-Fard S**. Autosomal recessive hypohidrotic ectodermal dysplasia caused by a novel mutation in EDAR gene. *International Journal of Pediatrics*. 2017 [accepted].
664. Miryounesi M, Salehpour S, Tonekaboni SH, Yassae VR, Nejabat M, Hashemi-Gorji F, Fardaei M, **Ghafouri-Fard S**. Neurodegeneration with brain iron accumulation 2A: report of four independent cases. *Metagene*. 2017 [accepted].
665. Seifi-Alan M, Shamsi R, **Ghafouri-Fard S**. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma. *Immunotherapy*. 2017 [accepted].
666. Noroozi R, Taheri M, Movafagh A, Mirfakhraie R, Darvish H, Sayad A, Inoko H, Noroozi H, Abedin Do A, Abbasi Soureshjani A, **Ghafouri-Fard S**. Association analysis of GABRB3 promoter variant with Autism in Iranian patients. *Basal ganglia*. 2017 [accepted].
667. **Ghafouri-Fard S**, Fardaei M, Tabei SMB, Dianatpour M, Miryounesi M. A CDH3 mutation is segregated in an Iranian family with congenital hypotrichosis and juvenile macular dystrophy. *International Journal of Pediatrics*. 2017 [accepted].
668. Taheri M, Omrani MD, **Ghafouri-Fard S**. Long non coding RNAs expression in bladder cancer. *Biophysical Review*. 2017 [accepted].
669. Mirzajani S, Mohebi M, Miryounesi M, Yassae VR, **Ghafouri-Fard S**. Genetic diagnosis of a lethal form of autosomal recessive polycystic kidney disease. *International Journal of Pediatrics*. 2017 [accepted].
670. Taheri M, Omrani MD, **Ghafouri-Fard S**. Long non coding RNAs expression in renal cell carcinoma. *Journal of Biology and Today's World*. 2017 Dec; 6 (12): 240-XX.
671. Faramarzi S, Dianatpour A, **Ghafouri-Fard S**. Discovering the role of long non-coding RNAs in regulation of steroid receptors signaling in cancer. *Journal of Biology and Today's World*. 2017 Dec; 6 (12): 248-XX.

672. Mohseni-Salehi F, Zare-Mirakabad F, **Ghafouri-Fard S**, Sadeghi M. The effect of stochasticity on repair of DNA double strand breaks throughout non-homologous end joining pathway. *Mathematical Medicine & Biology*. 2017 [accepted].
673. Motevaseli E, Khorramizadeh MR, Hadjati J, Farashi Bonab S, Eslami S, **Ghafouri-Fard S**. Investigation of antitumor effects of *Lactobacillus crispatus* SJ-3C-US in experimental model of breast cancer in BALB/c mice. *Immunotherapy*, 2017 [accepted].
674. Hatami M, Salmani T, Arsang-Jang S, Omrani MD, Mazdeh M, **Ghafouri-Fard S**, Sayad A, Taheri M. *STAT5a* and *STAT6* gene expression levels in multiple sclerosis patients. *Cytokine*, 2017 [accepted].
675. Taheri M, Noroozi R, Sayad A, **Ghafouri-Fard S**, Omrani MD. Integrin subunit alpha 4 (ITGA4) variant is associated with relapsing-remitting multiple sclerosis in an Iranian population. *Acta Medica Mediterranea*, 2017 [accepted].
676. Taheri M, Noroozi R, Sayad A, **Ghafouri-Fard S**, Omrani MD. Association study of Casitas B-lineage lymphoma proto-oncogene b (CBLB) gene variant and multiple sclerosis. *Acta Medica Mediterranea*, 2017 [accepted].
677. Shamsi R, Seifi-Alan M, Behmanesh A, Omrani MD, Mirfakhraie R, **Ghafouri-Fard S**. A bioinformatics approach for identification of miR-100 targets implicated in breast cancer. *Cellular and Molecular Biology*, 2017 [accepted].
678. Azimi T, **Ghafouri-Fard S**, Omrani MD, Mazdeh M, Arsang-Jang S, Sayad A, Taheri M. Vaccinia Related Kinase 2 (VRK2) expression in neurological disorders: schizophrenia, epilepsy and multiple sclerosis. *Multiple Sclerosis and Related Disorders*, 2017 [accepted].
679. Eftekharian MM, **Ghafouri-Fard S**, Soudyab M, Sayad A, Omrani MD, Komaki A, Mazdeh M, Taheri M. Expression analysis of long non coding RNAs in the blood of multiple sclerosis patients. *Journal of Molecular Neuroscience*, 2017 [accepted].
680. Dianatpour A, **Ghafouri-Fard S**. Long non coding RNAs expression: an intersection of cancer and spermatogenesis: A systematic review. *APJCP*, 2017 [accepted].
681. Mazdeh M, **Ghafouri-Fard S**, Noroozi R, Sayad A, Khani M, Taheri M, Omrani MD. Ecotropic Viral Integration Site 5 (*EVI5*) variants are associated with Multiple Sclerosis in Iranian population. *Multiple Sclerosis and Related Disorders*, 2017 [accepted].
682. Faramarzi S, **Ghafouri-Fard S**. Melanoma: a prototype of cancer-testis antigen expressing malignancies, *Immunotherapy*, 2017 [accepted].
683. Faramarzi S, **Ghafouri-Fard S**. Renal Cell Carcinoma: A Cancer-Testis Antigen Poor Malignancy. *Asian Pac J Cancer Biology*, 2017, 2(3): 1-4.
684. Faramarzi S, **Ghafouri-Fard S**. Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy. *Immunotherapy*, 2017 [accepted].

685. Mazdeh M, Eftekharian M, Omrani MD, Sayad A, Taheri M, **Ghafouri-Fard S**. Ecotropic Viral Integration Site 5 (EVI5) Expression Analysis in Multiple Sclerosis Patients. *Human Antibodies*, 2017 [accepted].
686. Ekrami M, Torabi M, **Ghafouri-Fard S**, Mowla J, Mohammad Soltani B, Hashemi-Gorji F, Mohebbi Z, Miryounesi M. Genetic Analysis of Iranian Patients with Familial Hypercholesterolemia, *Iranian Biomedical Journal*, 2017 [Epub ahead of print].
687. Memarrast F, **Ghafouri-Fard S**, Kolivand S, Jafary-Nodooshan S, Neyazi N, Sadroddiny E, Motevaseli E. Comparative evaluation of probiotics effects on plasma glucose, lipid and insulin levels in streptozotocin-induced diabetic rats. *Diabetes/Metabolism Research and Reviews*, 2017, 33 (7).
688. Sayad A, Noroozi R, Omrani MD, Taheri M, **Ghafouri-Fard S**. Retinoic acid-related orphan receptor alpha (*RORA*) variants are associated with autism spectrum disorder. *Metabolic Brain Disorders*, 2017 [Epub ahead of print].
689. Rahimi S, Taheri M, Moslemi E, **Ghafouri-Fard S**, Sayad A. Blood assessment of the expression levels of Matrix Metalloproteinase 9 (*MMP9*) and its natural inhibitor, *TIMP1* genes in Iranian schizophrenic patients. *Metabolic Brain Disorders*, 2017 [Epub ahead of print].
690. Sarrafzadeh S, Geranpayeh L, **Ghafouri-Fard S**. Expression analysis of long non-coding PCAT-1 in breast cancer. *IJHOSCR*, 2017 [Epub ahead of print].
691. Noroozi R, **Ghafouri-Fard S**, Omrani MD, Habibi M, Sayad A, Taheri M. Association study of the vesicular monoamine transporter 1 (*VMAT1*) gene with autism in an Iranian population. *Gene*, 2017, 625:10-14.
692. Nikpayam E, Soudyab M, Tasharrofi B, Sarrafzadeh S, Iranpour M, Geranpayeh L, Mirfakhraie R, Gharesouran J, **Ghafouri-Fard S**. Expression analysis of long non-coding ATB and its putative target in breast cancer. *Breast Disease*, 2017 [Epub ahead of print].
693. Azizi F, **Ghafouri-Fard S**. Outer Dense Fiber proteins: Bridging between Male Infertility and Cancer. *Archives of Iranian Medicine*, 2017, 20(5):320-325.
694. Taheri M, **Ghafouri-Fard S**, Solgi G, Sayad A, Mazdeh M, Omrani MD. Determination of cytokine levels in multiple sclerosis patients and their relevance with patients' response to Cinnovex. *Cytokine*, 2017, 96:138-143.
695. Motevaseli E, Dianatpour A, **Ghafouri-Fard S**. Probiotics role in cancer treatment: emphasis on their in vivo and in vitro anti-metastatic effects. *IJMCM*, 2017, 6(2), 66-76.
696. Sayad A, **Ghafouri-Fard S**, Omrani MD, Noroozi R, Taheri M. Myxovirus resistance protein A (*MxA*) polymorphism is associated with IFN β response in Iranian multiple sclerosis patients. *Neurological Sciences*, 2017, 38(6):1093-1099.

697. Taheri M, Pouresmaeili F, Omrani D, Habibi M, Noroozi R, Rakhshan A, Sayad A, **Ghafouri-Fard S**. Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population. *Biomarkers in Medicine*, 2017, 11(5), 413-422.
698. Taheri M, Habibi M, Noroozi R, Rakhshan A, Sayad A, Omrani MD, **Ghafouri-Fard S**. *HOTAIR* genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population. *Gene*, 2017, 613:20-24.
699. Eftekharian MM, Azimi T, **Ghafouri-Fard S**, Sayad A, Omrani MD, Sarrafzadeh S, Abbasalipourkabir R, Mazdeh M, Taheri M. Phospholipase D1 expression analysis in relapsing-remitting multiple sclerosis patients. *Neurological Sciences*. 2017, 38(5):865-872.
700. Taheri M, Omrani MD, Noroozi R, Sarrafzadeh S, **Ghafouri-Fard S**, Sayad A. Retinoic acid-related orphan receptor alpha (*RORA*) variants and risk of breast cancer. *Breast Disease Journal*. 2017 [Epub ahead of print].
701. Yazdandoost Hamedani S, Gharesouran J, Noroozi R, Sayad A, Omrani MD, Aghabozrg Afjeh S, Manoochehrabadi S, Toghi M, **Ghafouri-Fard S**, Taheri M. Ras-like without CAAX 2 (*RIT2*): a susceptibility gene for autism spectrum disorder. *Metabolic Brain Disease*. 2017, 32(3):751-755.
702. Dianatpour A, **Ghafouri-Fard S**. The Role of Long Non Coding RNAs in the Repair of DNA Double Strand Breaks. *IJMCM*. 2017 [Epub ahead of print].
703. Miryounesi M, Fardaei M, Tabei S M, **Ghafouri-Fard S**. Report of a case of autosomal recessive polycystic kidney disorder due to two novel compound heterozygote mutations in *PKHD1* gene referred to Comprehensive Medical Genetics Centre. *Tehran Univ Med J*. 2017; 74 (10).
704. **Ghafouri-Fard S**, Dianatpour M, Tabei SMB, Miryounesi M. Report of three cases of mental retardation due to chromosomal translocation in an Iranian consanguineous family. *Tehran Univ Med J*. 2017 [accepted].
705. Sarrafzadeh S, Taheri M, Geranpayeh L, Ghafouri-Fard S, **Ghafouri-Fard S**. Long non-coding RNA *GHET1* is possibly involved in the pathogenesis of a fraction of breast cancers. *IJCP*, 2017 [accepted].
706. Sarrafzadeh S, Geranpayeh L, Tasharrofi B, Soudyab M, Nikpayam E, Iranpour M, Mirfakhraie R, Gharesouran J, Ghafouri-Fard S, **Ghafouri-Fard S**. Expression study and clinical correlations of *MYC* and *CCAT2* in breast cancer patients. *IBJ*, 2017 [Epub ahead of print].
707. Safari MR, **Ghafouri-Fard S**, Noroozi R, Sayad A, Omrani MD, Komaki A, Eftekharian M, Taheri M. *FOXP3* Gene Variations and Susceptibility to Autism: A Case–Control Study, *Gene*, 2016, 596:119-122.
708. Tasharrofi B, Soudyab M, Nikpayam E, Iranpour M, Mirfakhraie R, Sarrafzadeh S, Geranpayeh L, Azargashb E, Sayad A, **Ghafouri-Fard S**. Comparative expression analysis of hypoxia inducible factor-alpha and its natural occurring antisense in breast cancer tissues and adjacent noncancerous tissues. *Cell Biochemistry and Function*, 2016, 34(8):572-578.

709. Khorshidi HR, Taheri M, Noroozi R, Sarrafzadeh S, Sayad A, **Ghafouri-Fard S**. ANRIL Genetic variants in Iranian breast cancer patients. *Cell*, 2017, 19(Suppl 1): 72–78.
710. Khorshidi HR, Taheri M, Noroozi R, Sarrafzadeh S, Sayad A, **Ghafouri-Fard S**. Investigation of the association of HOTAIR single nucleotide polymorphisms and risk of breast cancer in an Iranian Population. *Iranian Journal of Cancer Prevention*, 2016, 10(5):e7498.
711. Fardaei M, Tabei SM, Ghafouri-Fard S, Miryounesi M. A new mutation in *WT1* gene is associated with Wilms tumor with reduced penetrance in an Iranian family. *Iranian Journal of Cancer Prevention*, 2016 [accepted].
712. Salehpour S, Hashemi-Gorji F, Soltani Z, **Ghafouri-Fard S**, Miryounesi M. A novel nonsense mutation in *KLA1279* gene is associated with Goldberg-Shprintzen syndrome. *IJCN*, 2017, 11(1):70-74.
713. **Ghafouri-Fard S**, Yassaee VR, Rezayi A, Hashemi-Gorji F, Alipour N, Miryounesi M. A novel nonsense mutation in *PANK2* Gene in two patients with Pantothenate Kinase-Associated Neurodegeneration. *IJMCM*, 2016, 5(4):255-259..
714. **Ghafouri-Fard S**, Hashemi Gorji F, Fardaei M, Miryounesi M. Limb girdle muscular dystrophy type 2E due to a novel large deletion in *SGCB* gene. *IJCN*, 2016, 11(3), 57-60.
715. **Ghafouri-Fard S**, Hashemi-Gorji F, Yassaee VR, Alipour N, Miryounesi M. A novel splice site mutation in *HPS1* gene is associated with Hermansky-Pudlak syndrome-1 (HPS1) in an Iranian family. *IJMCM*, 2016, 5(3):192-195.
716. Nikpayam E, Tasharofi B, Sarrafzadeh S, **Ghafouri-Fard S**. The role of long non coding RNAs in ovarian cancer. *Iranian Biomedical Journal*, 2017, 21(1):3-15.
717. Soudyab M, Iranpour M, **Ghafouri-Fard S**. The role of long non coding RNAs in breast cancer, *Archives of Iranian Medicine*, 2016, 19(7):508-17.
718. **Ghafouri-Fard S**, Hashemi-Gorji F, Salehpour S, Yassaee V, Miryounesi M. A novel splice site mutation in *GNPTAB* gene in an Iranian patient with mucopolipidosis II alpha/beta. *JPEM*, 2016, 29(8):991-3.
719. Seifi-Alan M, Shamsi R, Setoodeh A, Sayarifard F, Aghasi P, Kompani F, **Ghafouri-Fard S**, Abbasi F. Autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy: report of two cases from Iran. *JPEM*, 2016, 29(8):979-83.
720. Taherian-Esfahani Z, Abedin-Do A, Nouri Z, Mirfakhraie R, **Ghafouri-Fard S**, Motevaseli E. Lactobacilli differentially modulate mTOR and Wnt/ β -catenin pathways in different cancer cell lines. *Iranian Journal of Cancer Prevention*, 2016, 15;9(3):e5369.

721. Gholami, M, Vatanparast M, Mirfakhraie R, iary A, Hosseini MM, **Ghafouri-Fard S**. Genetic Variants and Expression Study of FOXP3 Gene in Acute Coronary Syndrome in Iranian Patients. *Cell Biochemistry and Function*, 2016,34(3):158-62.
722. **Ghafouri-Fard S**, Salehpour S, Yassaee V, Miryounesi M. A new nonsense mutation in *CDKL5* gene in a male patient with early onset refractory epilepsy: a case report. *International Journal of Pediatrics*, 2016; 4(2): 1315-18.
723. Taherian-Esfahani Z, Abedin-Do A, Nikpayam E, Tasharofi B, Ghahghaei-Nezamabadi A, **Ghafouri-Fard S**. Cancer-Testis Antigens: a Novel Group of Tumor Biomarkers in Ovarian Cancers, *Iranian Journal of Cancer Prevention*, 2016, 9(6):e4993.
724. Miryounesi M, Dianatpour M, Motevaseli E, **Ghafouri-Fard S**. Homozygosity for a Robertsonian Translocation (13q;14q) in an Otherwise Healthy 44, XX. *Journal of Reproduction and Infertility*, 2016, 17(3):184-7.
725. Miryounesi M, Faraei M, Tabei MB, **Ghafouri-Fard S**. Leigh syndrome associated with a novel mutation in COX15 gene. *JPEM*,2016, 29(6):741-4.
726. Shokri F, Ghaedi H, **Ghafouri-Fard S**, Movafagh A, Abediankenari S, Abdolkarim M, Kashi Z, Omrani MD, Impact of ATM and SLC22A1 genetic variants on therapeutic response to metformin therapy in Iranian diabetic patients. *IJMCM*, 2016 Winter;5(1):1-7.
727. Esfandiary A, Abedin-Do A, Taherian-Esfahani Z, **Ghafouri-Fard S**, Motevaseli E. Intact expression of *hypoxia-inducible factor 1a (HIF-1a)* gene in HeLa cell line following treatment with *lactobacilli* supernatants. *IJCP*, 2016 [In press].
728. Fardaei M, Sarrafzadeh S, **Ghafouri-Fard S**, Miryounesi M. Autosomal recessive non-syndromic hearing loss: a case report with a mutation in *TRIOBP* gene. *IJMCM*, Autumn 2015, 4(4), 245-7.
729. Esfandiary A, Taherian-Esfahani Z, Abedin-Do A, Mirfakhraie R, Shirzad M, **Ghafouri-Fard S**. Lactobacilli modulate hypoxia-inducible factor (HIF)-1 regulatory pathway in triple negative breast cancer cell line. *Cell (Yakhteh)*, 2015 [accepted].
730. Iranpour M, Soudyab M, Geranpayeh L, Mirfakhraie R, Azargashb E, Movafagh A, **Ghafouri-Fard S**. Expression analysis of four long noncoding RNAs in breast cancer, *Tumor Biology*, 2015 [ahead of print].
731. Abedin-Do A, Taherian-Esfahani Z, **Ghafouri-Fard S**, Ghafouri-Fard S, Motevaseli E. Immunomodulatory effects of Lactobacillus strains: emphasis on their effects on cancer cells, *Immunotherapy*, 2015;7(12):1307-29.
732. **Ghafouri-Fard S**, Seifi-Alan M, Shamsi R, Esfandiary A. Immunotherapy in multiple myeloma using cancer-testis antigens. *Iranian Journal of Cancer Prevention*, 2015, 8(5):e3755.
733. **Ghafouri-Fard S**, Fardaei M, Miryounesi M. A novel 5 nucleotide deletion in *XPA* gene is associated with severe neurological abnormalities. *Gene*, 2016, 576(1 Pt 2):379-80.

734. **Ghafouri-Fard S**, Fardaei M, Gholami M, Miryounesi M. A case report: Autosomal recessive microcephaly caused by a novel mutation in *MCPH1* gene. *Gene*, 2015 571(1):149-50
735. **Ghafouri-Fard S**. Expression of Cancer-Testis Antigens in Pediatric Cancers. *APJCP*, 2015;16(13):5149-5152.
736. **Ghafouri-Fard S**, Fardaei M, Bagheri Lankarani K, Miryounesi M. Segregation of a novel *MLH1* mutation in an Iranian Lynch syndrome family, *Gene*, 2015; 570: 304–305.
737. Imani Saber Z, **Ghafouri-Fard S**. *In Silico* Interaction and Docking Studies Indicate a New Mechanism for PML Dysfunction in Gastric Cancer and Suggest Imatinib as a Drug to Restore Function. *APJCP*, 2015; 16(12): 5005-5006.
738. Miryounesi M, **Ghafouri-Fard S**, Fardaei M. A novel missense mutation in *CLCN1* gene in a family with autosomal recessive congenital myotonia. *Iranian Journal of Medical Sciences*, 2016, 41(5): 456–458.
739. Esfandiary A, **Ghafouri-Fard S**. MAGE-A3: an immunogenic target used in clinical practice, *Immunotherapy*, 2015, 7(6):683-704.
740. Esfandiary A, **Ghafouri-Fard S**. New York esophageal squamous cell carcinoma-1 and cancer immunotherapy, *Immunotherapy*, 2015; 7(4), 411-439.
741. Imani-Saber Z, Yousefi-Razin E, Javaheri M, Mirfakhraie R, Motalleb G, **Ghafouri-Fard S**. PML gene mutations may not contribute in gastric adenocarcinoma. *APJCP*, 2015; 16(8), 3523-3525.
742. **Ghafouri-Fard S**. Expression of cancer-testis antigens in stem cells: Is it a potential drawback or an advantage in cancer immunotherapy? *APJCP*, 2015; 16(7): 3079-81.
743. Miryounesi M, Dianatpour M, Shadmani Z, **Ghafouri-Fard S**. Report of a case with trisomy 9 mosaicism, *Iranian Journal of Medical Sciences*, 2015 [accepted].
744. Abbasi F, Azizi F, Javaheri M, Mosallanejad A, Ebrahim-Habibi A, **Ghafouri-Fard S**. Segregation of a novel 6 nucleotide deletion in *GLUT2* gene in a Fanconi-Bickel syndrome family, *Gene*, 2015;557(1):103-5.
745. Motevaseli E, Azam, R, Akrami SM, Mazlomy MA, Saffari M, Modarressi MH, **Ghafouri-Fard S**, Daneshvar M. *Lactobacillus crispatus* and *Lactobacillus rhamnosus* culture supernatants effects on expression of autophagy genes and HPV E6 and E7 oncogenes in HeLa cell line, *Cell*, 2016, 17(4), 583-756.
746. Kazemi G, **Ghafouri-Fard S**, Mobasheri MB, Geranpayeh L, Modarressi MH. Upregulation of *RHOXF2* and *ODF4* Expression in Breast Cancer Tissues Compared to Adjacent Normal Tissues, *Cell*, 2015, 17(3), 471- 477.

747. Mansouri N, Movafagh A, Sayad A, **Ghafouri-Fard S**, Darvish H, Zare-Abdollahi D, Emamalizadeh B, Shahvaisizadeh F, Ghaedi H, Bastami M, Kayyal M, Hashemi M, Heidari M, Nejatizadeh A, Zamani M. Hepatitis B virus infection in patients with blood disorders: a concise review in pediatric study. *Iran J Ped Hematol Oncol*. 2014;4(4):178-87
748. Miryounesi M, **Ghafouri-Fard S**, Goodarzi H, Fardaei M, A new missense mutation in the BCKDHB gene causes the classic form of Maple syrup urine disease (MSUD), *Journal of Pediatrics Endocrinology and Metabolism*, 2014; 28(5-6):673-5.
749. Imani Saber Z, **Ghafouri-Fard S**. Promyelocytic leukemia (PML) Gene and its Role in Tumorigenesis. *Asian Pac J Cancer Prev*. 2014, 15(19), 8021-8028.
750. **Ghafouri-Fard S**, Rezazadeh F, Zare-Abdollahi D, Omrani MD, Movafagh A. Are So-Called Cancer-Testis Genes Expressed Only in Testis? *Asian Pac J Cancer Prev*. 2014, 15(18): 7703-7705.
751. **Ghafouri-Fard S**, Abbasi F, Azizi F, Javaheri M, Mehdizadeh M, Setoodeh A. Hyperostosis-hyperphosphatemia syndrome (HHS): report of two cases with a recurrent mutation and review of the literature. *Journal of Pediatrics Endocrinology and Metabolism*, 2014; 28(1-2):231-5.
752. Azam R, **Ghafouri-Fard S**, Tabrizi M, Modarressi MH, Ebrahimzadeh-Vesal R, Daneshvar M, Mobasheri MB, Motevaseli E. Lactobacillus acidophilus and Lactobacillus crispatus Culture Supernatants Downregulate Expression of Cancer-testis Genes in the MDA-MB-231 Cell Line. *Asian Pac J Cancer Prev*. 2014;15(10):4255-9.
753. Abbasi F, **Ghafouri-Fard S**, Javaheri M, Dideban A, Ebrahimi A, Ebrahim-Habibi A. A new missense mutation in FGF23 gene in a male with hyperostosis–hyperphosphatemia syndrome (HHS). *Gene* 2014, 542(2):269-71.
754. **Ghafouri-Fard S**, Nekoohesh L, Motevaseli E. Bladder Cancer Biomarkers: Review and Update. *APJCP*. 2014, 15(6), 2395-403.
755. **Ghafouri-Fard S**, Shamsi R, Seifi-Alan M, Javaheri M, Tabarestani S. Cancer-Testis Genes as Candidates for Immunotherapy in Breast Cancer. *Immunotherapy*. 2014, 6(2): 165-179.
756. Seifi-Alan M, Shamsi R, **Ghafouri-Fard S**, Mirfakhraei R, Zare-Abdollahi D, Movafagh A, Modarressi MH, Kazemi G, Geranpayeh L, Najafi-Ashtiani M. Expression Analysis of Two Cancer-Testis Genes, FBXO39 and TDRD4 in Breast Cancer Tissues and Cell Lines. *APJCP*. 14 (11), 6625-6629.
757. Safari S, Zare-Abdollahi D, Mirfakhraie R, **Ghafouri-Fard S**, Pouresmaeili F, Movafagh A, Omrani D. An Iranian family with azoospermia and premature ovarian insufficiency segregating NR5A1 mutation. *Climacteric*. 2013 Jun;17(3):301-3.
758. Asadi M, **Ghafouri-Fard S**, Zare Abdollahi D, Ebrahim-Habibi A, Matin N. Estrogen receptor mutation in a girl with primary amenorrhea, *Clinical Genetics*, 2013, 83(5):497-8.
759. Tabarestani S, **Ghafouri-Fard S**. Cancer Stem Cells and Response to Therapy, *Asian Pac J Cancer Prev*, 2012,13(12):5951-8.

760. Dianatpour M, Mehdipour P, Nayernia K, Mobasheri MB, **Ghafouri-Fard S**, Savad Sh, Modarressi MH. Expression of Testis Specific Genes TSGA10, TEX101 and ODF3 in Breast Cancer, Iran Red Crescent Med J. 2012, 14(11):722-6.
761. **Ghafouri-Fard S**, Zare Abdollahi D, Omrani MD, Azizi F. shRNA Mediated RHOXF1 Silencing Influences Expression of BCL2 but not CASP8 in MCF-7 and MDA-MB-231 Cell Lines, APJCP. 2012,13(11):5865-9.
762. **Ghafouri-Fard S**, Ghafouri-Fard S. siRNA and Cancer Immunotherapy. Immunotherapy, 2012, 4(9):907-17.
763. **Ghafouri-Fard S**, Ghafouri-Fard S, Modarressi MH. Expression of splice variants of cancer-testis genes ODF3 and ODF4 in the testis of a prostate cancer patient. Genetic and Molecular Research, 2012, 11(4):3642-8
764. **Ghafouri-Fard S**, Ghafouri-Fard S. Immunotherapy in nonmelanoma skin cancer. Immunotherapy, 2012, 4(5), 499–510.
765. **Ghafouri-Fard S**. Are Cancer-Testis Antigens Cancer Stem Cell Markers? J Sing Cel Genom Proteomics. 2012, 1:1.
766. **Ghafouri-Fard S**, Modarressi MH. Expression of Cancer-Testis Genes in Brain Tumors: Implications for Cancer Immunotherapy. Immunotherapy, 2012, 4(1), 59-75.
767. **Ghafouri-Fard S**, Modarressi MH, Yazarloo F. Expression of Testis Specific Genes, TEX101 and ODF4, in CML and Evaluation of TEX101 Immunogenicity. Ann Saudi Med. 2012 May-Jun, 32(3), 256-61.
768. **Ghafouri-Fard S**, Akrami SM. MAN EVOLUTION: AN ISLAMIC POINT OF VIEW. European Journal of Science and Theology, 2011, 7(3), 13-27.
769. **Ghafouri-Fard S**, Ousati Ashtiani Z, Sabah Golian B, Hasheminasab SM, Modarressi MH. Expression of Two Testis Specific Genes, SPATA19 and LEMD1 in Prostate Cancer. Archives of Medical Research. 2010, 41(3): 195-200.
770. **Ghafouri-Fard S**, Abbasi A, Moslehi H, Faramarzi N, Taba Taba Vakili S, Mobasheri MB, Modarressi MH. Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features.Br J Dermatol. 2010, 162(4):772-9.
771. **Ghafouri-Fard S**, Modarressi MH. Cancer-Testis Antigens: Potential Targets for Cancer Immunotherapy. Archives of Iranian Medicine 2009, 12(4): 395-404.
772. Larijani B, Zahedi F, **Ghafouri-Fard S**. Rewarded gift for living renal donors. Transplantation Proceedings 2004, 36: 2539-2542.

773. Larijani B, **Ghafouri-Fard S**, Zahedi F. Ethical Considerations in Clinical Education of Medical Students. Iranian Journal of Diabetes and Lipid Disorder. 2004; 4 (Supplement (Ethic in Clinical Researchs)):105-107.
774. **Ghafouri-Fard S**, Sadeghi S, Ramezanzade F, Aghahoseini M, Alyasine A, Shariat M, et al. A Review of compiling of Ethical Guidelines for Gamete and Fetus Research in Iran. J Babol Univ Med Sci 2006; 8(Suppl.3):43-7.

RESEARCH INTERESTS

- Cancer biology (LncRNAs expression profile)
- Pharmacogenetic and genetic aspects of multiple sclerosis
- Optimization Algorithms (Neural Networks and Artificial Intelligence in autism)
- Genetics of psychiatric disorders (Autism, Schizophrenia, ADHD, Depression, Bipolar disorder)

LANGUAGES

- Persian: Native
- Arabic: Advance
- English: Fluent

ACADEMIC WORK EXPERIENCES

- Head of Medical Genetics Department, Shahid Beheshti University of medical sciences, 2021 to present.
- Head of Talented and gifted of Shahid Beheshti University of Medical Sciences.

SKILLS

- **General Computer Skills:** Microsoft office.
- **Experimental Skills:** PCR, Real-Time PCR, HLA Typing, Western Blotting, Cell culture, Gel Electrophoresis, HRM, MLPA, Sanger Sequencing, whole Exome Sequencing
- **Software:** Rest, Linreg, SPSS, Allele Id, Beacon designer, DNAMAN
- **Bioinformatics:** Basic statistics in R